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Abstract: Die septische Granulomatose (engl. chronic granulomatous disease, CGD) ist eine Gruppe von
primären Immundefekten, die durch Mutationen in für die Phagozyten Nikotinamid Adenin Dinucleotid
Phosphat (NADPH) Oxidase kodierenden Genen (gp91phox, p22phox, p47phox, p67phox, and p40phox)
bedingt ist. CGD Phagozyten produzieren keine reaktiven Sauerstoffverbindungen (engl. reactive oxy-
gen species, ROS), töten Mikroben schlecht ab und betroffene Patienten leiden daher an rezidivierenden
lebensbedrohlichen Infektionen mit Bakterien und Schimmelpilzen. Aspergillus spp. Infektionen, die
Pneumonien und disseminierte Infektionen hervorrufen können, sind die Haupttodesursache von CGD
Patienten. Bisher war es unklar, wie gesunde Neutrophile Granulozyten Aspergillus Spezies kontrollieren.
Wir haben daher die Rolle von NADPH Oxidase abhängigen extrazellulären Neutrophilen Fallen (eng.
Neutrophil Extracellular Traps, NETs) in Hinsicht auf die anti- Aspergillus Abwehr bei Patienten mit
CGD untersucht. NETs werden nach Aktivierung von Neutrophilen freigesetzt und bestehen aus Chro-
matin (DNA und Histone), das mit granulären und zytoplasmatischen antimikrobiellen Proteinen besetzt
ist. NETs binden und halten Bakterien und Pilze gefangen und setzen sie antimikrobiellen Proteinen aus.
Die Bildung von NETs benötigt zwingend ROS, die von der NADPH Oxidase produziert werden. Daher
können CGD Neutrophile keine NETs bilden. Wir haben erstmals gezeigt, dass mikrobizide NETs gegen
A. nidulans Konidien und Hyphen in vitro wirksam sind, und dass die Rekonstitution der NADPH Oxi-
dase Aktivität durch Gentherapie (GT) bei einem Patienten mit X-chromosomal vererbter CGD die NETs
Bildung wiederhergestellt hat. Dies hat zur Ausheilung einer schweren invasiven A. nidulans Infektion
in vivo beigetragen. Wir haben ferner die kritische Rolle von NET-Assoziiertem Calprotectin demonstri-
ert, das mittels Zink- Sequestrierung Dosis-abhängig eine fungistatische oder fungizide anti-Aspergillus
Wirkung hat. GT für CGD soll den Defekt der NADPH Oxidase Untereinheiten durch die Insertion
einer normalen Kopie des verantwortlichen defekten Gens in autologe hämatopoetischen Stammzellen
des jeweiligen Patienten funktionell korrigieren und die Krankheit dauerhaft heilen. In internationaler
Kollaboration wurden kürzlich in unserer Abteilung für Immunologie/Hämatologie/KMT am Univer-
sitätskinderspital Zürich ￿-retrovirale GT Vektoren in klinischen Phase I/II Studien kürzlich ausführlich
getestet und die klinische Wirksamkeit der GT für X-chromosomale CGD (gp91phox Defekt) gezeigt.
Allerdings machen unerwartete Nebenwirkungen wie Ausschalten (Silencing) der Transgenaktivität und
Transaktivierung von Onkogenen eine Verbesserung der Vektoren-Effizienz und -Sicherheit vor künftigen
klinischen GT Studien an CGD Patienten zwingend nötig. Chronic granulomatous disease (CGD) is
a group of primary immunodeficiencies caused by mutations in genes encoding phagocyte nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase subunits (gp91phox, p22phox, p47phox, p67phox, and
p40phox). CGD phagocytes do not produce reactive oxygen species (ROS), kill microbes poorly and con-
sequently patients are susceptible to recurrent life-threatening bacterial and fungal infections. Aspergillus
spp. infections, which cause pneumonia and disseminated disease, are the leading cause of death in CGD
patients. Up to now it was unclear how neutrophils control Aspergillus species in healthy individuals. We
therefore set out to study the role of NADPH oxidase dependent neutrophil extracellular traps (NETs)
in anti-Aspergillus defense in CGD. NETs are released after neutrophil activation and are composed of
chromatin (DNA and histones) decorated with granular and cytoplasmic proteins. NETs bind and trap
bacteria and fungi and expose antimicrobial molecules. Generation of NETs requires ROS produced by
the NADPH oxidase; therefore CGD neutrophils cannot release NETs. We showed for the first time
that the microbicidal pathway through NETs is efficient against A. nidulans conidia and hyphae in vitro,
and that restoration of NET formation was achieved by complementation of NADPH oxidase function
by gene therapy (GT) in a patient with X-linked CGD. This aided clearing severe invasive A. nidulans
infection in vivo. We demonstrated the critical role of NET- associate calprotectin for dose-dependent
fungistatic of fungicidal anti-Aspergillus activity by Zn2+ sequestration. Gene therapy (GT) for CGD
aims at functional correction of the NADPH oxidase subunit defects by insertion of a normal copy of
the responsible gene into autologous patient derived hematopoietic stem cells (HSC) to cure the disease.
￿-retroviral GT vectors have been extensively studied in international collaboration in recent phase I/II
clinical GT for X- linked (gp91phox-deficient) CGD in our Division of Immunology/Haematology/BMT
at University Children’s Hospital Zurich, proving feasibility of this approach. However, unexpected side
effects like transgene silencing and oncogene transactivation impose improvements in vector efficacy and
safety for future clinical GT trials. We therefore developed and functionally studied next generation
￿-retroviral self- inactivating (SIN) vectors as candidates for future clinical X-CGD GT trials. Among the
myelospecific vectors tested in vitro, we identified the human MRP8 and miRNA-223 promoters as most
efficient in driving gp91phox expression, leading to ROS production and NET formation in differentiated
human X-CGD hematopoietic stem cells.
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Zusammenfassung 
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Zusammenfassung 
Die septische Granulomatose (engl. chronic granulomatous disease, CGD) ist eine Gruppe 
von primären Immundefekten, die durch Mutationen in für die Phagozyten Nikotinamid 
Adenin Dinucleotid Phosphat (NADPH) Oxidase kodierenden Genen (gp91phox, p22phox, 
p47phox, p67phox, and p40phox) bedingt ist. CGD Phagozyten produzieren keine reaktiven 
Sauerstoffverbindungen (engl. reactive oxygen species, ROS), töten Mikroben schlecht ab 
und betroffene Patienten leiden daher an rezidivierenden lebensbedrohlichen Infektionen mit 
Bakterien und Schimmelpilzen. Aspergillus spp. Infektionen, die Pneumonien und 
disseminierte Infektionen hervorrufen können, sind die Haupttodesursache von CGD 
Patienten. Bisher war es unklar, wie gesunde Neutrophile Granulozyten Aspergillus Spezies 
kontrollieren. 
Wir haben daher die Rolle von NADPH Oxidase abhängigen extrazellulären 
Neutrophilen Fallen (eng. Neutrophil Extracellular Traps, NETs) in Hinsicht auf die anti-
Aspergillus Abwehr bei Patienten mit CGD untersucht. NETs werden nach Aktivierung von 
Neutrophilen freigesetzt und bestehen aus Chromatin (DNA und Histone), das mit granulären 
und zytoplasmatischen antimikrobiellen Proteinen besetzt ist. NETs binden und halten 
Bakterien und Pilze gefangen und setzen sie antimikrobiellen Proteinen aus. Die Bildung von 
NETs benötigt zwingend ROS, die von der NADPH Oxidase produziert werden. Daher 
können CGD Neutrophile keine NETs bilden. Wir haben erstmals gezeigt, dass mikrobizide 
NETs gegen A. nidulans Konidien und Hyphen in vitro wirksam sind, und dass die 
Rekonstitution der NADPH Oxidase Aktivität durch Gentherapie (GT) bei einem Patienten mit 
X-chromosomal vererbter CGD die NETs Bildung wiederhergestellt hat. Dies hat zur 
Ausheilung einer schweren invasiven A. nidulans Infektion in vivo beigetragen. Wir haben 
ferner die kritische Rolle von NET-Assoziiertem Calprotectin demonstriert, das mittels Zink-
Sequestrierung Dosis-abhängig eine fungistatische oder fungizide anti-Aspergillus Wirkung 
hat. 
GT für CGD soll den Defekt der NADPH Oxidase Untereinheiten durch die Insertion 
einer normalen Kopie des verantwortlichen defekten Gens in autologe hämatopoetischen 
Stammzellen des jeweiligen Patienten funktionell korrigieren und die Krankheit dauerhaft 
heilen. In internationaler Kollaboration wurden kürzlich in unserer Abteilung für 
Immunologie/Hämatologie/KMT am Universitätskinderspital Zürich γ-retrovirale GT Vektoren 
in klinischen Phase I/II Studien kürzlich ausführlich getestet und die klinische Wirksamkeit 
der GT für X-chromosomale CGD (gp91phox Defekt) gezeigt. Allerdings machen unerwartete 
Nebenwirkungen wie Ausschalten (Silencing) der Transgenaktivität und Transaktivierung von 
Onkogenen eine Verbesserung der Vektoren-Effizienz und -Sicherheit vor künftigen 
klinischen GT Studien an CGD Patienten zwingend nötig. 
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Daher haben wir als Kandidaten für künftige klinische X-CGD GT Studien die nächste 
Generation von γ-retroviralen Selbst-Inaktivierenden (SIN) Vektoren entwickelt und 
funktionell getestet. Unter den in vitro getesteten myelospezifischen Vektoren, haben wir die 
humanen MRP8 und miRNA-223 Promotoren als am effizientesten in Hinsicht auf die 
Expression des gp91phox Transgens, ROS Produktion und NETs Bildung in humanen 
differenzierten X-CGD hämatopoetischen Stammzellen identifiziert. 
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Summary 
Chronic granulomatous disease (CGD) is a group of primary immunodeficiencies caused by 
mutations in genes encoding phagocyte nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase subunits (gp91phox, p22phox, p47phox, p67phox, and p40phox). CGD phagocytes 
do not produce reactive oxygen species (ROS), kill microbes poorly and consequently 
patients are susceptible to recurrent life-threatening bacterial and fungal infections. 
Aspergillus spp. infections, which cause pneumonia and disseminated disease, are the 
leading cause of death in CGD patients. Up to now it was unclear how neutrophils control 
Aspergillus species in healthy individuals. 
We therefore set out to study the role of NADPH oxidase dependent neutrophil 
extracellular traps (NETs) in anti-Aspergillus defense in CGD. NETs are released after 
neutrophil activation and are composed of chromatin (DNA and histones) decorated with 
granular and cytoplasmic proteins. NETs bind and trap bacteria and fungi and expose 
antimicrobial molecules. Generation of NETs requires ROS produced by the NADPH 
oxidase; therefore CGD neutrophils cannot release NETs. We showed for the first time that 
the microbicidal pathway through NETs is efficient against A. nidulans conidia and hyphae in 
vitro, and that restoration of NET formation was achieved by complementation of NADPH 
oxidase function by gene therapy (GT) in a patient with X-linked CGD. This aided clearing 
severe invasive A. nidulans infection in vivo. We demonstrated the critical role of NET-
associate calprotectin for dose-dependent fungistatic of fungicidal anti-Aspergillus activity by 
Zn2+ sequestration. 
Gene therapy (GT) for CGD aims at functional correction of the NADPH oxidase 
subunit defects by insertion of a normal copy of the responsible gene into autologous patient 
derived hematopoietic stem cells (HSC) to cure the disease. γ-retroviral GT vectors have 
been extensively studied in international collaboration in recent phase I/II clinical GT for X-
linked (gp91phox-deficient) CGD in our Division of Immunology/Hematology/BMT at University 
Children’s Hospital Zurich, proving feasibility of this approach. However, unexpected side 
effects like transgene silencing and oncogene transactivation impose improvements in vector 
efficacy and safety for future clinical GT trials. 
We therefore developed and functionally studied next generation γ-retroviral self- 
inactivating (SIN) vectors as candidates for future clinical X-CGD GT trials. Among the 
myelospecific vectors tested in vitro, we identified the human MRP8 and miRNA-223 
promoters as most efficient in driving gp91phox expression, leading to ROS production and 
NET formation in differentiated human X-CGD hematopoietic stem cells. 
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Chapter overview 
The main subject of the described work is the phagocyte nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase deficient disorder chronic granulomatous disease (CGD), with 
regard to the role of neutrophil extracellular trap (NET) formation in the CGD disease process 
and the correction of NADPH oxidase function by gene therapy for CGD. This introductory 
chapter, therefore, focuses on CGD, the NADPH oxidase, the role of NETs in innate 
immunity against infection, and retroviral vectors as gene delivery system for human 
haematopoietic stem cell gene therapy. 
 
Chronic granulomatous disease 
CGD is a primary immunodeficiency that affects the oxidative mechanism of microbial killing 
of phagocytic cells. It was first described in the 1950s, termed fatal granulomatous disease of 
childhood 1-3. The defect is due to absent or severely impaired activity of the NADPH oxidase 
of phagocytes (neutrophils, monocytes, macrophages and eosinophils), resulting in 
inadequate generation of reactive oxygen species (ROS), necessary for microbicidal activity 
within the phagosome, and lack of NETs 4-6. Patients usually present early in life with 
recurrent and often life-threatening bacterial and fungal infections, and may develop chronic 
inflammatory granuloma in viscera and skin. 
CGD occurs with an estimated frequency of 1 in 200’000 live births as a consequence 
of mutations in mainly one of five genes encoding the structural subunits of the NADPH 
oxidase complex (gp91phox, p22phox, p47phox, p40phox, and p67phox) 7. Approximately 65% of all 
cases result from mutations in the gp91phox encoding CYBB gene (X-CGD) localized on the 
X-chromosome, autosomal-recessive forms are caused in 25% by NCF1 gene mutations 
encoding p47phox, while only 5% of cases are due to mutations in p67phox encoding NCF2 and 
p22phox encoding CYBA 8 (these four forms of CGD are referred to as X91, A47, A67, and 
A22, respectively, with X for X-linked and A for autosomal 9). Recently, one family with 
p40phox encoding NCF4 mutation has been described 10. 
The diagnosis of CGD is usually made by assessing NADPH oxidase function via 
measurement of nitroblue tetrazolium (NBT) reduction, or dihydrorhodamine (DHR) 
oxidation. DHR is preferable because of its relative ease of use, its ability to distinguish X-
linked from autosomal patterns of CGD by flow cytometry, and its sensitivity to very low 
numbers of functional neutrophils 11. 
 
Clinical features of CGD 
CGD is characterized by predisposition to severe, recurrent infection with bacteria and fungi 
12. CGD patients usually present within the first years of life with cervical or inguinal 
lymphadenitis, liver abscess, osteomyelitis, pneumonia, or skin abscesses 13 (Table 1). 
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Rarely CGD is diagnosed in only adulthood 14,15. The microorganisms responsible for the 
majority of infections in CGD are S. aureus, Gram-negative enteric bacilli (including Serratia 
marcescens, Salmonella species, and Burkholderia cepacia) and Aspergillus species. 
Catalase-negative bacteria are rarely involved in CGD infection because of microbe-
generated H2O2 in the phagosomes of neutrophils 13,15,16. 
 
Table 1. Most common manifestations of CGD by organ system 
Organ Frequency Most common manifestation of CGD Unique features Most common infecting organisms 
 
Lungs 
 
80% 
 
Pneumonia 
 
Contiguous spread to chest wall, associated 
osteomyelitis of ribs or vertebral bodies 
 
Aspergillus, Staphylococcus 
Lymph nodes 60% Suppurative adenitis Thick, enhancing septa; calcifications in chronic 
disease 
Staphylococcus 
Liver 25-50% Hepatic abscess Multiple small abscesses without an inciting event Staphylococcus aureus 
Muscoskeletal 25% Osteomyelitis Multifocal; occurs in ribs, vertebral bodies, small 
bones of hands and feet 
Serrantia marcescens, Aspergillus 
Gastrointestinal 17% Bowel wall thickening, mimics inflammatory 
bowel disease 
Thickening of the wall of the gastric antrum Granulomatous inflammation occurs in the 
absence of identifiable infection 
Genitourinary 10-13% Urinary tract infections Inflammatory pseudotumor of the bladder Has not been reported 
Head and neck 12-15% Sinusitis Fungal sinusitis Has not been reported 
Central nervous system 4-5% Encephalitis, brain abscess, meningitis Abscesses have typical imaging appearance Candida meningitis 
 
Adapted from 17. 
 
Patients with CGD also suffer from a variety of inflammatory conditions 13,18,19, 
including granuloma formation. Granulomas may be of microscopic or macroscopic size (up 
to several centimeters). Microscopic granulomas are typically part of a diffuse inflammatory 
process, such as colitis, while macroscopic granulomas usually cause a localized pathology 
through mechanical disturbance, such as gastric outlet obstruction. Granuloma formation can 
affect various organs, with a preference for hollow viscera, such as colon, stomach, and 
bladder. A number of observations argue in favor of a non-infectious origin of CGD 
granulomas, while the primary mechanism of the increased inflammatory response remains 
poorly understood 20-22. 
Pneumonia and/or sepsis due to Aspergillus and Burkholderia are the most common 
causes of death in CGD patients 13. X-linked CGD patients have been reported to have more 
severe clinical complications and higher mortality rates (5% vs 2% per year) than those with 
A47 CGD 13. Female carriers of X91 CGD, with as few as 10% NADPH oxidase positive 
neutrophils, are asymptomatic 12. 
 
Conventional treatment of CGD 
The current treatment options for CGD are summarized in Table 2. Long-term antibiotic and 
antimycotic prophylaxis is the mainstay of treatment for CGD patients. Interferon-gamma 
(IFN-γ) has been shown to increase NADPH oxidase activity in some rare variants of X91 
CGD with splice site mutations by improving splicing efficiency, resulting in generation of 
small amounts of functional gp91phox. Donor granulocyte transfusions have been used for the 
treatment of life-threatening bacterial and fungal infections 23, limited by the risk of 
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alloimmunization to HLA antigens which may complicate subsequent allogeneic 
haematopoietic stem cell transplantation (HSCT). 
 
Table 2. CGD: main treatment modalities 
Modality Indication Duration Drug 
 
Antibiotic prophylaxis 
 
Bacterial infections 
Fungal infections 
 
Lifelong 
Lifelong 
 
Trimethoprim-sulfamethoxazole 
Itraconazole 
Empiric antibiotic treatment Gram+ infections 
Gram− infections 
Fungal infections 
Until pathogen identification 
Until pathogen identification 
Until pathogen identification 
Teicoplanin 
Ciprofloxacin 
Voriconazole 
Interferon-γ prophylaxis Recurrent infections Lifelong Interferon-γ 
White cell transfusion Severe refractory infections Until recovery of antibody formation G-CSF stimulated leukocytes 
Anti-inflammatory treatment Obstructing granuloma 7-10 days → taper Prednisolone 
Stem cell transplantation Recurrent serious manifestations LAF-isolation 2 months, isolation at home 6-9 months HLA identical marrow transplant 
 
LAF, laminar air flow; G-CSF, granulocyte colony-stimulating factor; HLA, human leukocyte antigen. Adapted from 24. 
 
HSCT is currently the only curative option for CGD patients, provided an HLA-
identical donor is available 12,24-26. The overall HSCT success rate is 81%, with an overall 
mortality of 15% 27. Unfortunately, an HLA-identical donor is only available for 52% of CGD 
patients 28, and graft-versus-host disease (GvHD) and inflammatory flare-up at infectious 
sites are major risks associated with HSCT 27. New studies with non-myeloablative reduced-
intensity conditioning and HLA-identical donors provide encouraging results, reducing toxicity 
induced by myeloablative conditioning and reducing the risk of GvHD 29,30. 
Gene therapy approaches for patients needing HSCT but lacking a compatible HSC 
donor have been developed, and will be discussed later on. 
 
Neutrophils 
Neutrophils are professional phagocytes indispensable for defense against intruding 
microorganisms. They are generated in large number in the bone marrow and circulate in 
blood for a few hours. If microorganisms have successfully overcome the physical barriers 
provided by the skin and mucus membranes and gained access to tissues, signals generated 
by microbes and resident macrophages at sites of infection activate the local endothelial 
cells, which capture bypassing neutrophils and guide them across the endothelial cell lining. 
Products generated by live microorganisms and by their interaction with soluble proteins that 
recognize microorganisms guide neutrophils toward the microbes, which are taken up by 
phagocytosis. 
Neutrophils degrade microorganisms using a combination of oxidative and non-
oxidative mechanisms (Fig. 1). Once phagocytosed, microorganisms are sequestered in the 
phagolysosome. Subsequent activation of the NADPH oxidase system generates large 
quantities of ROS. Release of ROS into the phagolysosome constitutes the oxidative arm of 
the microbicidal action of neutrophils. Traditionally, ROS were thought to be responsible for 
the direct killing of microorganisms. Intracellular sequestration of microorganisms also 
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induces the fusion of neutrophil granules with the phagolysosome and the release of 
antimicrobial peptides and proteases from the granules into the phagolysosome. The action 
of these antimicrobial peptides and proteases constitutes the non-oxidative arm of the 
microbicidal action of neutrophils 31, acting by directly disrupting the microbial cell membrane 
32,33. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Neutrophils deliver multiple anti-microbial molecules from azurophilic granules (also known as 
primary granules), specific granules (also known as secondary granules) and tertiary granules, plasma 
and phagosomal membranes, the nucleus and the cytosol. BPI, bactericidal permeability increasing 
protein; H2O2, hydrogen peroxide; HOBr, hypobromous acid; HOCl, hypochlorous acid; HOI, hypoiodous 
acid; MMP, matrix metalloproteinase; 1O2, singlet oxygen; O2-, superoxide; O3, ozone; •OH, hydroxyl 
radical; phox, phagocyte oxidase. From 34. 
 
Besides their direct antimicrobial activity, extracellularly released granule proteins 
contribute to microbial clearance by recruitment and activation of monocytes and 
macrophages 35 and by enhancing phagocytosis of pathogens by macrophages 36,37. 
 
Neutrophil NADPH oxidase 
The phagocyte NADPH oxidase consists of several proteins that are segregated between 
membrane and cytosol in resting cells (Fig. 2) 38-40: flavocytochrome b558 is the central 
membrane-associated component of the NADPH oxidase and is composed of the 
glycosylated protein gp91phox (phox for phagocyte oxidase), non-covalently bound in a 1:1 
stabilized complex to the p22phox subunit, which is essential for maturation and stable 
expression of flavocytochrome b558. The cytosolic NADPH oxidase subunits are p40phox, 
p47phox, and p67phox, which interact with each other (with a 1:1:1 stoichiometry) to form a 
complex, and the small G-proteins, Rac1 (in monocytes) or Rac2 (in neutrophils). The spatial 
separation of the NADPH oxidase components ensures that the enzyme is dormant in resting 
cells; in response to stimulation, the cytosolic components migrate almost instantly to the 
membrane where they assemble with flavocytochrome b558 to form the active enzyme, a 
process that is tightly regulated by protein-protein interactions and by phosphorylation 41,42. 
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Figure 2. ROS generation by assembly of Phox proteins in phagocytes. Activation of the NADPH oxidase 
system occurs by at least three signaling triggers that result in the assembly of cytosolic regulatory 
proteins (p40phox, p47phox and p67phox) with the membrane-associated catalytic subunits gp91phox and 
p22phox (flavocytochrome b558). These triggers involve protein kinases, lipid-metabolizing enzymes and 
nucleotide-exchange proteins that activate the GTPase RAC. Protein kinases catalyze phosphorylation of 
the autoinhibitory region of p47phox, allowing its binding to p22phox. Phosphatidylinositol 3-kinase (PI3K) 
produces 3-phosphorylated phosphatidylintositols (PtdInsP), providing lipids to which the p47phox and 
p40phox bind. Finally, activation of exchange factors (GEF) triggers GTP binding to RAC, resulting in 
conformational changes that promote dissociation from RhoGDI, membrane association and binding to 
p67phox, helping to assemble the active complex. From 43. 
 
The gp91phox subunit is the electron transfer chain of the active NADPH oxidase and 
comprises binding sites for FAD, NADPH, and two hemes. Long thought to be specific to 
phagocytes, gp91phox is now known to belong to a large family of proteins expressed in many 
different cell types and called NOX for NADPH oxidase, of which NOX2 is the phagocyte 
protein 44. In resting cells, 60-70% of flavocytochrome b558 is located in the membranes of 
specific granules, 20-25% of flavocytochrome b558 is located in the membranes of 
gelatinase granules, while the remainder is found in plasma membranes and the membrane 
of secretory vesicles 45,46. Properties of all NADPH oxidase components are summarized in 
table 3. 
The NADPH oxidase subunits regulate their interaction with each other, with the 
membrane proteins and with lipids 41,42. The structure of the cytosolic complex of resting cells 
is not entirely defined; however, p67phox has been shown to associate tightly with p40phox, and 
p47phox has the ability to interact with both p40phox and p67phox 41,42. In resting cells, Rac2, 
which is more abundant in human neutrophils than Rac1 (92% homologous to Rac2), is also 
present in the cytosol but is not part of the cytosolic complex. In its resting cytosolic GDP 
form, Rac2 is bound to its inhibitor, rho-GDI 47. When neutrophils are activated and 
exocytosis of granules occurs, fusion of granule membranes with the plasma membrane 
increases the expression of flavocytochrome b558 45,48, thought to be the central docking site 
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for the 10–20% of the cytosolic NADPH oxidase components that translocate to the plasma 
membrane upon stimulation 47,49-51. The activation is accompanied with extensive 
phosphorylation of p47phox on several serines located in the polybasic region of the carboxy-
terminal portion of the protein 52, designated as the auto-inhibitory region. This results in the 
unmasking of cryptic SH3 domains, which can then bind the proline-rich region of p22phox 53. 
Other interactions with gp91phox/NOX2 domains tether p47phox at the membrane. The p47phox 
subunit is thought to be responsible for transporting the cytosolic complex to the membrane 
during oxidase activation 49-51 and is considered as the organizer of the active NADPH 
oxidase complex. The p67phox subunit is also phosphorylated during activation 54, although to 
a lesser degree than p47phox. At the membrane, it binds to flavocytochrome b558 55 and 
regulates its activity 56. It also binds to Rac2 (or Rac1), which translocates to the plasma 
membrane independently and interacts with the p67phox/flavocytochrome b558 complex 41,42. 
p40phox is weakly phosphorylated during activation 57. It is not required for NADPH oxidase 
activation in a cell-free system but it has a positive stimulatory effect on enzyme activation in 
vitro 58. On the contrary, p47phox, p67phox, and Rac, like flavocytochrome b558, are essential 
for optimal NADPH oxidase activation in a cell-free system and in intact neutrophils 38,39,41,42. 
 
Table 3. Properties of the phagocyte respiratory burst oxidase components 
 gp91phox p22phox p47phox p67phox p40phox Rac2 
Gene and locus CYBB; Xp21.1 CYBA; 16q24 NCF-1; 7q11.23 NCF-2; 1q25 NCF-4; 22q13.1 Rac2; 22q13.1 
Amino acids 570 195 390 526 339 192 
Molecular weight: 
   Predicted 
   By SDS-PAGE 
 
65.338 kDa 
90 kDa 
 
20.959 kDa 
22 kDa 
 
44.684 kDa 
47 kDa 
 
59.735 kDa 
67 kDa 
 
39.039 kDa 
40 kDa 
 
21.429 kDa 
22 kDa 
Glycosylation Yes No No No No No 
pI 9.26 10.1 9.58 6.12 7.28 7.87 
Phosphorylation No Minor Yes Minor Yes Unknown 
Location in PMN 
   Resting 
 
   Stimulated 
 
Specific granules and 
plasma membrane 
Plasma membrane and 
phagosome 
 
Specific granules and 
plasma membrane 
Plasma membrane and 
phagosome 
 
Cytosol 
 
Membrane 
 
Cytosol 
 
Membrane 
 
Cytosol 
 
Membrane 
 
Mainly cytosol 
 
Membrane 
Aboundance pmol/106 
cells (cytosol conc.) 1.0-2.0 1.0-2.0 6.0 (2750 nM) 1.0 (460 nM) 1.0 (460 nM) 2.6 (1200nM) 
Functional domains 
 
 
 
 
C-terminus binds 
cytosolic components. 
Haem, FAD and 
NADPH binding regions 
C-terminal proline-rich 
region 
Phosphorylation sites, 
PX domain, 2 SH3 
domains, proline-rich 
domain 
Tetratricopeptide repeat, 
2 SH3 domains, proline-
rich domain 
PX and SH3 domains, 
octicosapeptide repeat 
GDP/GTP-binding; 
insert and effector 
regions, isoprenylation 
site 
 
Adapted from 40. 
 
Generation of reactive oxygen species 
ROS production by activated NADPH oxidase begins with superoxide (O2-) formation by the 
following reaction 59: 
 
NADPH + 2O2   NADP+ + H+ + 2O2- 
 
Two molecules of superoxide then react to generate hydrogen peroxide (H2O2) in a 
dismutation reaction, accelerated by the enzyme superoxide dismutase (SOD). In the 
presence of iron, superoxide and H2O2 react to generate hydroxyl radicals. In addition to 
NADPH oxidase 
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superoxide, H2O2 and hydroxyl radicals, other ROS occur in vivo: in inflamed tissue, these 
include hypochlorous acid (HOCl), formed within neutrophils from H2O2 and chloride by the 
phagocyte enzyme myeloperoxidase (MPO); singlet oxygen, which might be formed from 
oxygen through the action of NADPH oxidase and MPO-catalysed oxidation of halide ions 60; 
and ozone, which can be generated from singlet oxygen by antibody molecules (regardless 
of source of antigenic specificity) 61. Formation and reactivity of ROS is schematically 
resumed in figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Superoxide generation. Superoxide is generated from various sources, which include the 
NADPH oxidase (phox). The color coding indicates the reactivity of individual molecules: from green 
(relatively unreactive) to red (high reactivity and non-specificity). From 43. 
 
Neutrophil extracellular traps 
In 2004, Arturo Zychlinsky et al described a new NADPH oxidase dependent antimicrobial 
mechanism of neutrophils, called neutrophil extracellular traps (NETs) 62, which extend 
neutrophil’s antimicrobial action against bacteria 62, parasites 63, and fungi 4,64 beyond 
neutrophil death. Formation of NETs (Fig. 4) is an alternative to death by necrosis or 
apoptosis. During so called netosis, the nuclei swell and the chromatin is dissolved. Large 
strands of decondensed DNA are extruded from the cell, carrying along proteins from 
cytosol, granules, and histones 6,62,65. 24 neutrophil proteins have been shown associated 
with NETs 66: NET proteins are primarily the cationic (thus, DNA-binding) bactericidal 
proteins: histones, defensins, elastase, proteinase 3, heparin binding protein, cathepsin G, 
lactoferrin, and myeloperoxidase 66, but also the pattern recognition molecule Pentraxin 3 67.  
The mechanism of NET formation is not yet completely known. It has been shown 
that decondensation of chromatin is associated with citrullination of Histone H3 by 
conversions of histone arginine to citrulline residues by peptidylarginine deiminase 4 (PAD4) 
68, an enzyme which is particularly rich in mature neutrophils 69. Elastase released from 
azurophil granules degrades histones and synergizes with myeloperoxidase to drive 
chromatin decondensation 70. NET formation is dependent on H2O2 generated by NADPH 
oxidase and further metabolized by myeloperoxidase (MPO). CGD neutrophils and MPO-
deficient neutrophils, therefore, do not form NETs 4,6,71. Moreover, the NADPH oxidase-
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activated Raf-MEK-ERK pathway is implicated in NET formation by inhibiting apoptosis to 
allow netosis 72. 
 
 
 
 
 
Figure 4. NET formation. Transmission (a-d) and scanning (e) electron microscopy of PMA-activated 
neutrophils. (a) Unstimulated neutrophils show a lobulated nucleus with clearly defined eu- and 
heterochromatin and numerous cytoplasmic vacuoles. (b) After 60 min of stimulation, nuclei are less 
lobulated. (c) After 120 min, most nuclei no longer show separation of eu- and heterochromatin, and in 
some cells the nuclear envelope starts to disintegrate into a chain of vesicles surrounding the DNA 
(arrows). (d) After 180 min of stimulation, most neutrophils are nearly entirely filled with decondensed 
chromatin, ready to be released. (e) Released NET-DNA after 240 min of stimulation. Adapted from 6. 
 
The full contribution of NETs to overall antimicrobial activity versus the classical 
microbicidal activity of phagocytosing neutrophils in vivo has not yet been established. There 
is also evidence that NETs can contribute to pathological conditions: release of NETs in the 
blood stream has been reported in case of severe sepsis, ensnaring bacteria in the 
circulation but with the expense of injury to endothelium and tissues 73. Moreover, the release 
of high levels of DNA and cellular content could play a role during development of 
autoimmune diseases like systemic lupus erythematosis (SLE). SLE patients have 
autoantibodies against DNA-associated proteins such as the ones found in NETs. A subset 
of patients has been identified with decreased activity of DNase-1, a NET-degrading protein 
found in plasma 74. These patients had enhanced risk of nephritis. Furthermore, it was shown 
that SLE NETs participate to the chronicle activation of plasmacytoid dendritic cells (pDC) 
75,76, a key point in SLE pathogenesis. It was also reported that NETs can induce thrombosis 
by stimulating platelets in vitro, and NET components were abundant in thrombi induced in a 
baboon model 77. NETs were also found to damage activated human endothelial cells in 
culture 78, and seem to be involved in the pathogenesis of preeclampsia 79 and psoriasis 80. 
All these observations point to a potential proinflammatory role of NETs. 
 
Gene therapy 
Gene therapy (GT) for primary immunodeficiency disease aims at functional correction of a 
genetic defect, to date by insertion of a normal and active copy of the responsible gene 
(transgene) into autologous patient hematopoietic stem cells (HSC) to cure the disease. 
Different strategies have been adopted to functionally correct the defective genes of interest. 
Replication-incompetent retroviral vectors are presently the most frequent studied tools for 
delivery of a therapeutic transgene into HSC. Retroviral transgene vectors enter the target 
e 
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cell, reverse transcribe and integrate the therapeutic gene into the host genome, from where 
it is expressed (Fig. 5). 
 
Packaging cell line
3. Transduction
Vector RNA
Double-stranded DNA
Nucleus
Cell genome
gp91phox
Cytoplasm
Transgene vector
γ-retroviral particle
Functional 
NADPH-Oxidase
4. Integration
5. Expression
gp91phoxLTR LTR
Gag
Pol
Vector RNA
Env
Reverse
transcriptase
gp91
p22
p67
p47
O2-
O2
2. Production
p40
6. Function
1. Cloning
 
Figure 5. Schematic representation of a γ-retrovirally mediated X-CGD gene therapy. 
 
To selectively target HSC with the retroviral vector and to avoid transduction of other 
tissues, standard GT uses G-CSF mobilized HSC isolated by apheresis from patient’s 
peripheral blood. HSC are then retrovirally transduced ex vivo. At the end of the transduction 
period, corrected cells and the subset of cells that were not susceptible to transduction are 
reinfused into the patient and home to the bone marrow. Engraftment of the corrected cells 
and clinical success of gene therapy depend on: i) the transduction efficiency of the most 
primitive HSC 81; ii) an eventual selective growth advantage of the corrected cells; iii) the 
chimerism of corrected and non-corrected (resident cells and transplanted non-transduced 
cells) engrafting cells; and iv) the persistence of transgene expression. The level of 
transgene expression is critical for functional correction. It depends on the promoter used 
and can later be hampered by methylation of the enhancer/promoter and by surrounding 
chromatin elements. The chimerism (percentage of transgene carrying cells) and the level of 
transgene expression are particularly critical for diseases such as CGD, where no selective 
growth advantage is conferred by the transgene. 
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Native retroviruses 
Retroviridae are a family of single-stranded (ss) RNA viruses. The retroviral particle contains 
two copies of positive-strand RNA, which are complexed with nucleocapsid protein, together 
with the enzymes reverse transcriptase, integrase, and protease. A second protein shell, 
formed by capsid protein, encloses the nucleocapsid and delimits the viral core. Matrix 
proteins form a layer outside the core and interact with a cell-derived lipid envelope which 
incorporates viral envelope glycoproteins (env), responsible for the interaction with specific 
cellular receptors. Two units form these glycoproteins: the transmembrane, which anchors 
the protein into the lipid bilayer, and the surface, which binds to the cellular receptor. 
Based on their genome organization, the Retroviridae are divided in simple and 
complex retroviruses. Examples are oncoretroviruses, such as murine leukemia virus (MLV), 
and lentiviruses, such as human immunodeficiency virus (HIV), respectively. Their genome is 
organized in the gag, pro, pol, and env genes (Fig. 6A). Gag (group-specific antigen) 
encodes the structural proteins, pro (protease) encodes the protease essential for gag 
cleavage during maturation, and pol (polymerase) gene encodes the enzymes that 
accompany the ssRNA. Of these, reverse transcriptase carries out reverse transcription of 
the viral RNA to DNA, integrase catalyses the integration of the proviral DNA into the host 
genome, and protease is involved in gag-pol cleavage and virion maturation. Env (envelope) 
encodes the viral envelope. In addition, complex retroviruses have accessory genes whose 
concerted action regulates viral gene expression, assembly, and replication. Moreover, the 
retroviral genome contains cis-acting sequences, such as two long terminal repeats (LTR), 
with elements required for gene expression. Other important components are the packaging 
signal (psi or ψ), required for the specific RNA packaging into newly formed virions, and the 
polypurine tract (PPT), which is the site of the initiation of positive-strand DNA synthesis 
during reverse transcription. 
The retroviral life cycle starts with the binding of the viral envelope to its cellular 
receptor and fusion of the viral envelope with the cell membrane. Subsequently, the particle 
is uncoated and the viral core released into the cytoplasm. The ssRNA is reverse-transcribed 
into double-stranded (ds) DNA within the core, which is transported to the nucleus upon cell 
division for oncoretroviruses, or through active transport in the case of lentiviruses. The 
major advantage of lentiviruses over oncoretroviruses is their ability to transduce non-
dividing cells. Once in the nucleus, the viral DNA is integrated into the host DNA (provirus), 
resulting in long-term expression of viral genes which are transcribed and spliced during the 
life of the infected cell. The full-length viral RNA as well as the RNA encoding all the viral 
proteins are transported to the cytoplasm, where they are translated. The unspliced full-
length viral RNA is packaged and a viral particle assembled. Virion maturation occurs 
together with budding of the particle from the cell, as such resulting in new infectious virions. 
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Retroviral vectors as gene delivery system 
The use of gene delivery vectors based on retroviruses was introduced in the early 1980s 82. 
The most commonly used retroviral vectors are based on MLV (Fig. 6B). They can transfer 7 
to 9 kb of foreign genetic information, which is sufficient for most therapeutic transgenes. The 
retroviral vectors used in GT applications are replication defective. In these vectors the 
genetic information elementary for virus production (gag, pro, pol and env genes) is deleted 
and is provided in trans during virus production by packaging cell lines. By changing virus 
envelope proteins the target cell specificity of the viral vector can be modified: for clinical 
HSC transduction, vectors pseudotyped with amphotropic MLV or gibbon ape leukemia virus 
(GALV) envelope have been used. HSC are heterogeneous with respect to their 
susceptibility to retroviral transduction, as transduction efficiency mainly depends on the type 
of retrovirus (gamma (γ)-, lenti-, e.g. MLV or HIV, respectively), the virus vector envelope 
(pseudotyping) and the cell cycle status of the HSC 83. Unlike γ-retroviruses, which are 
dependent on cell division for integration, lentiviruses are able to transverse the intact 
nuclear membrane of a non-dividing HSC but are still more efficient at entering the nucleus 
during mitosis 84. As HSC are quiescent at initiation of ex vivo culture, efficient transduction 
protocols with γ-retrovirus vectors require 3-4 days of ex vivo culture; whereas transduction 
protocols with lentiviral vectors can be as short as 1-2 days. In the last 15 years much 
progress has been achieved in the development of viral vectors derived from lentiviruses 
(such as HIV). A very important issue for lentiviral vectors has always been the biosafety with 
respect to the pathogenicity of the parental virus. The wild type HIV virus encodes the vif, 
vpr, vpu and nef genes. Their products are dispensable for virus production but are involved 
in HIV pathogenesis. In third generation lentiviral vectors these genes have been deleted, 
strongly improving the safety of these vectors 85-87. 
 
 
 
 
Figure 6. Retroviral vector development for GT. (A) Structure of a simple retroviral genome (e.g. MLV) 
containing coding sequences for gag, pro, pol, and env for replication. (B) Structure of a γ-retroviral self-
inactivating (SIN) vector for GT. IP, internal (tissue-specific) promoter; CI, chromatin insulator; WPRE, 
woodchuck hepatitis virus post-transcriptional element. 
 
First successful clinical gene therapy trials for primary immunodeficiency 
The first successful clinical GT was reported by Fischer and Cavazzana-Calvo in 2000 88 in 
two patients with the X-linked form of severe combined immune deficiency (SCID-X1) due to 
deficiency of the common gamma chain (γc) cytokine receptor. Overall, ten patients with 
SCID-X1 were treated, and achieved long-lasting immune reconstitution. The potentially 
curative outcome of gene therapy for SCID-X1 was later confirmed by Gaspar and Thrasher 
R U5U3 gag pro pol env R U5U3
ψ PPT
5’ LTR 3’ LTR
R U5∆U3 IP Transgene CI WPRE R U5∆U3
ψ PPT
5’ SIN-LTR 3’ SIN-LTR
B A 
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in Great Britain, who reported successful reconstitution of immunity in ten patients with SCID-
X1 89,90. 
Bone marrow conditioning for GT was introduced in 2002 by Aiuti and colleagues who 
treated adenosine deiminase (ADA)-deficient SCID patients with low dose busulfan prior to 
infusion of transduced CD34+ HSC, with the goal of improving the engraftment of gene 
corrected cells 91. To date, data on thirty patients have been reported 92 indicating long-term 
multilineage engraftment of gene-corrected cells, associated with improvement in T-cell 
counts and proliferation to exogenous stimuli. 
Both SCID-X1 and ADA-SCID GT trials lead to clear clinical benefits. Unfortunately, 
serious adverse events have been reported for five SCID-X1 patients, who developed 
leukemia due to transactivation events caused by the retroviral vector (insertional 
mutagenesis) 93-95. No serious adverse events due to transactivation have been observed in 
the ADA-SCID trials so far 92. 
 
Gene therapy for CGD 
CGD is considered a suitable candidate for a GT approach, as all genes encoding for the 
subunits of the NADPH oxidase have been cloned. Moreover, data from variant forms of 
CGD and from healthy carriers of X91 CGD with as few as ≥ 10% normal neutrophils suggest 
that functional correction of a minor fraction of CGD neutrophils could be sufficient to cure 
the disease 8. This observation together with a potential synergistic effect on antifungal 
activity of gene-corrected neutrophils and defective neutrophils in antifungal activity 96 have 
motivated the development of a GT protocol for CGD 97. 
 
Early unsuccessful CGD gene therapy trials 
Clinical GT trials for CGD were first initiated in the mid-1990s. The first of these were 
conducted by Malech and colleagues at the National Institutes of Health (USA): five patients 
with autosomal-recessive CGD (p47phox deficiency) were transfused with autologous CD34+ 
HSC after genetic modification with a p47phox-expressing γ-retroviral vector 98. After 
transduction, HSC (0.1-4.7 x 106 cells/kg) were reinfused into the patients without bone 
marrow conditioning. Although the level of functionally corrected granulocytes after in vitro 
differentiation of transduced HSC was high (21-90%), the percentage of functionally 
corrected granulocytes circulating in vivo was low (0.004 to 0.05% of total peripheral blood 
granulocytes) and persisted at this level for up to 6 months after reinfusion. The same group 
initiated a similar trial for X-CGD in 1998. Several modifications were included in this 
protocol, including enhanced mobilization of CD34+ HSC using Flt3-ligand (Flt3L) and 
granulocyte-macrophage colony-stimulating factor (GM-CSF), and retroviral transduction 
performed on 4 subsequent days resulting in an initial transduction efficiency of 48 to 89%. 
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Despite these modifications, the level of functionally corrected cells in peripheral blood still 
only ranged between 0.2 and 0.6% at 3-4 weeks after reinfusion and remained at this level 
for the next 4-6 months 97. A third similar study was conducted by Dinauer and colleagues at 
Indiana University (USA). Autologous CD34+ HSC from two adult X-CGD patients were 
transduced using a murine stem cell virus-based bicistronic γ-retroviral vector (MSCV-91Neo) 
containing the gp91phox and the neomycin-resistance genes using a standard retronectin-
based protocol. In this case, superoxide production was detected in both patients at up to 
0.1% of peripheral blood neutrophils and persisted at this level for almost 9 months post-
infusion (unpublished data, see.99). 
One common denominator in these early clinical trials was the lack of bone marrow 
conditioning or myelosuppression that is conventionally used during allogeneic 
transplantation procedures 27. Because gene-corrected CGD cells are not predicted to have 
a selective advantage over non-transduced cells (in contrast to SCID), engraftment of 
sufficient numbers of HSC to provide long-term correction is now considered to be possible 
only when bone marrow conditioning is performed or when a marker gene is co-expressed 
for in vivo selection. 
 
Later successful CGD gene therapy trials 
In 2006 bone marrow conditioning was successfully adopted on a study reported by Ott et al. 
and Stein et al, in which our Division of Immunology/Hematology/BMT at Zurich University 
was implied. CD34+ cells obtained from two young adult X-CGD patients (age 25 and 26 
years) were transduced using a γ-retroviral vector (SF71gp91phox) containing a gp91phox 
complementary DNA under the transcriptional control of the spleen focus-forming virus 
(SFFV) LTR 100,101 (the protocol used is summarized in figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Zurich-Frankfurt X-CGD GT protocol. Isolated peripheral blood stem cells (PBSC) of CGD 
patients were first enriched by CD34+ selection and then pre-stimulated during 36 hours with a cocktail of 
cytokines (SCF, Flt3L, TPO and IL-3) to induce cell division. CD34+ HSC were retrovirally transduced 3 
times over 3 days and finally reinfused into the patients after low-dose Busulfan bone marrow 
conditioning. 
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Transduction efficiencies ranged between 40 and 45%, with 65-95% of the cells retaining 
expression of CD34 at the end of the 5-day transduction period. Transduced cells were 
reinfused at a dose between 9.0 and 11.3 x 106 CD34+ cells/kg after reduced intensity 
conditioning with liposomal busulfan at a total dose of 8 mg/kg. Approximately 15% of 
peripheral blood neutrophils were found to express gp91phox within the first 5 months after 
transplantation, this number increasing thereafter. The same vector and protocol were 
successfully used later by our Division to treat two children with X-CGD (manuscript in 
preparation). One of the children, an 8.5-year-old boy, suffered from therapy refractory 
Aspergillus nidulans lung infection 4. Transduction efficiency reached 33% and the patient 
was transplanted with 18.2 x 106 CD34+ total cells/kg after reduced intensity conditioning with 
busulfan intravenously (total dose 8.8 mg/kg). Gene marking in peripheral blood granulocytes 
was around 20% at day 20 after GT and remained stable until day 86, the last observation 
day reported in this study. Functionally corrected neutrophils were detected in the peripheral 
blood of this patient at levels between 30% (day 20) and 16% (day 86). The life-threatening, 
therapy refractory A. nidulans infection was cleared during the first six weeks after GT. 
 
Risks of gene therapy using γ-retroviral vectors 
Unfortunately, despite encouraging clinical results, the first GT trials for SCID-X1 also 
highlighted substantial risks of the procedure: considering all patients treated in the French 
and British trials, 5 patients out of 20 developed leukemia caused by the insertion of the 
therapeutic vector near LMO2, a known T-cell oncogene. Deregulation of LMO2 induced by 
the murine leukemia virus (MLV) enhancer was concluded to be the basis of the leukemic 
event 93-95,102. 
In the CGD GT trial reported by Ott et al., the percentage of peripheral blood 
neutrophils expressing gp91phox increased from 5 months after transplantation due to the 
insertional activation of growth-promoting genes, in particular PRDM16 and MDS1/EVI1 100. 
The overexpression of EVI1 lead to clonal dominance and ultimately monosomy 7 and 
myelodysplasia in both adult patients 101. Moreover, a gradual loss of NADPH oxidase 
expressing neutrophils occurred 8 months after GT, caused by epigenetic inactivation 
(silencing) of the vector resulting in <5% superoxide-producing neutrophils (month 26 and 45, 
respectively). Gene-marked cells were still detectable, but CpG methylation within the 
promoter of the viral LTR resulted in reduced gp91phox transgene expression. Enhancer 
elements of the viral LTR were not methylated and lead to oncogene transactivation. 
 
Future of γ-retroviral gene therapy 
The occurrence of unexpected severe adverse events in SCID-X1 and CGD GT trials has 
stimulated extensive preclinical research aimed at reducing the risk of insertional 
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oncogenesis and vector silencing in future applications. The tendency of γ-retroviral vectors 
to integrate near transcription start sites of transcriptionally active genes 90,103-106 and the 
intrinsic promoter enhancing activity of retroviral LTRs are now known to be critical risk 
factors. To overcome the latter, self inactivating (SIN) 107 γ-retroviral vectors have been 
developed (Fig. 6B) for GT of SCID-X1 108. SIN-vectors lack the enhancer sequences of 
retroviral LTRs and are therefore less prone to activating promoters near integration sites 
109,110. These vectors require an internal promoter to drive transgene expression. Cell culture 
111 and in vivo 112 assays showed that SIN-vectors with a strong viral internal 
enhancer/promoter have significantly lower transformation frequency by insertional 
mutagenesis compared to their LTR-driven counterparts 109. Replacement of the strong viral 
promoter with weaker and tissue-specific cellular promoters further reduced transactivation 
activity 113. The use of myeloid-specific promoters in CGD GT could target transgene 
expression to differentiated phagocytes and could at the same time avoid the use of strong 
enhancers potentially active in HSC. Addition of the ubiquitously-acting chromatin opening 
element (UCOE), which displays no enhancer function, has also been shown to have 
reduced transactivational activity compared to viral LTR promoters. Moreover, UCOE has 
been shown to resist silencing and to confer persistent transgene expression in a mouse 
study 114. In addition, chromatin insulators such as the chicken β-globin hypersensitive site 4 
have been used successfully to shield the surrounding chromatin from the vector and vice 
versa the vector from influences by the surrounding chromatin, resulting in less position-
dependent silencing and in less position-effect variegation 115. 
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Objectives of the study 
CGD patients are highly susceptible to severe recurrent Aspergillus infection. Despite the 
routine use of antifungal prophylaxis, life-threatening Aspergillus infections have remained a 
serious problem. A. fumigatus and A. nidulans are the most common Aspergillus species in 
CGD, with A. nidulans infection being associated to significantly higher mortality (50% versus 
6% ). Up to now it was unclear how neutrophils control Aspergillus hyphae, which are too 
large for phagocytosis, in healthy individuals. We hypothesized that NADPH oxidase-
dependent NET formation might be involved in anti-Aspergillus defense, as NET formation is 
defective in CGD. 
 
Objective 1: To determine whether gene therapy (GT) restores NET formation in 
CGD by complementation of NADPH oxidase function, and whether NETs have antimicrobial 
activity against Aspergillus nidulans (see chapter 1). 
 
Objective 2: To determine the antifungal agent and mechanism responsible for 
reconstitution of Aspergillus growth inhibition within NETs after complementation of NADPH 
oxidase function by GT for CGD (see chapter 2). 
 
To date allogeneic HSCT from an HLA identical donor is the only proven curative treatment 
for CGD, but is hampered by the availability of suitable HSC donors (only available for 52% 
of patients) and conditioning-regimen related toxicity. GT approaches to cure CGD have 
been clinically successful, but still face two major risks: oncogene transactivation and 
silencing of the transgene. Future GT vectors therefore have to balance sufficient transgene 
expression/efficiency with a minimum of transactivation activity. 
 
Objective 3: To develop new GT (SIN) vectors with improved safety and efficiency 
profiles, for next generation phase I/II clinical CGD GT trials, and to develop a model to study 
NET formation after gene correction of CGD cells (see chapter 3). 
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Abstract 
Chronic granulomatous disease (CGD) patients have impaired nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase function, resulting in poor antimicrobial activity of 
neutrophils including the inability to generate Neutrophil Extracellular Traps (NETs). Invasive 
aspergillosis is the leading cause of death in patients with CGD; it is unclear how neutrophils 
control Aspergillus species in healthy individuals. The aim of this study was to determine 
whether gene therapy (GT) restores NET formation in CGD by complementation of NADPH 
oxidase function, and whether NETs have antimicrobial activity against Aspergillus nidulans. 
Here we show that reconstitution of NET formation by GT in a patient with CGD restores 
neutrophil elimination of Aspergillus nidulans conidia and hyphae and is associated with 
rapid cure of pre-existing therapy refractory invasive pulmonary aspergillosis, underlining the 
role of functional NADPH oxidase in NET formation and antifungal activity. 
 
Introduction 
Activated neutrophils kill microbes intracellularly following phagocytosis and by extracellular 
mechanisms including Neutrophil Extracellular Traps (NETs), which are composed of 
chromatin decorated with granular proteins 1. NETs bind bacteria 1 and fungi 2 and expose 
antimicrobial molecules. Generation of NETs requires reactive oxygen species (ROS) 
produced by the NADPH oxidase 3. 
Chronic granulomatous disease (CGD) is caused by mutations in genes encoding 
NADPH oxidase subunits. CGD patients do not produce ROS, kill microbes poorly and are 
susceptible to recurrent life-threatening infections 4. Aspergillus spp. infections cause 
pneumonia and disseminated disease and are the leading cause of death in these patients 4-
6. 
It is unclear how Aspergillus infections are controlled in healthy individuals 7-13. In 
CGD patients, these infections are frequently refractory to antifungal therapy, treatment with 
interferon-γ, or granulocyte transfusions 5. Here we show that the recently discovered 
NADPH oxidase dependent microbicidal pathway through NETs 1-3 is efficient against A. 
nidulans conidia and hyphae in vitro, and that restoration of NET formation by GT of X-CGD 
aided clearing severe invasive A. nidulans infection in vivo. 
 
Methods 
Gene therapy 
We treated an 8.5-year-old boy with X-linked gp91phox-deficient CGD and therapy refractory 
A. nidulans lung infection with a monocistronic long terminal repeat-driven gammaretroviral 
SF71gp91phox vector (see supplemental data). The protocol for the patient’s treatment was 
approved by the ethics review board of the University Children’s Hospital Zurich and the 
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Swiss Expert Committee for Bio-Safety, after written informed consent from his parents in 
accordance with the Declaration of Helsinki. For follow-up monitoring, gp91phox expression 
was measured by fluorescence-activated cell sorter (FACS) on peripheral neutrophils after 
30 min staining at room temperature with 10 µg/ml gp91phox-fluorescin isothiocyanate (FITC) 
antibody (Anti-Flavocytochrome b558, clone 7D5, MBL). NADPH oxidase activity was 
measured by standard dihydrorhodamine (DHR) and nitroblue tetrazolium (NBT) tests 
(supplemental materials). Bone marrow colony assays and determination of proviral gp91phox 
sequences in genomic DNA were performed as described 14. 
NET induction 
NET formation was visualized as described (supplemental materials) and quantified after 
stimulation of 5x104 neutrophils for 3h with 40nM phorbol 12-myristate 13-acetate (PMA) and 
staining the NET-DNA with 1 µM Sytox green (Invitrogen) in a black 96-well plate (BD 
Biosciences). The plates were read in a fluorescence microplate reader (Victor3, PerkinElmer 
Life and Analytical Sciences) with a filter setting of 485/535nm (excitation/emission). 
NET antifungal activity 
The A. nidulans strain used was isolated from bronchoalveolar lavage fluid of the patient; 
conidia were grown and collected as described 7. Neutrophils after GT were stained with 
gp91phox-FITC antibody and sorted by FACS (FACSAria, BD Biosciences) into gp91phox-
negative (gp91phox-) and -positive (gp91phox+) populations. 105 neutrophils were activated with 
PMA (40nM) at 37°C for 4h in a 96-well plate, then infected with conidia (multiplicity of 
infection A. nidulans/neutrophils 0.5) ± prior digestion of NETs with 10 U/ml of Micrococcal 
Nuclease (MNase, Worthington Biochemical) for 30 min. Afterwards the plates were 
centrifuged 5 min at 400 g and incubated for 16h at 37°C, allowing germination and hyphal 
outgrowth. Alternatively, 5x104 conidia were incubated for 12 h at 37°C to allow hyphal 
outgrowth; then 105 neutrophils were added, centrifuged 5 min at 400 g and incubated for 2 
and 5 h with PMA (40nM) to induce NET formation, ± 10 U/ml MNase. Fungal growth was 
quantified with XTT (Invitrogen) as described 15. 
 
Results and discussion 
In healthy subjects NETs might be essential to eliminate fungi since hyphae are too large to 
be phagocytosed 7,9,12,13,16-21. CGD patients are unable to make NETs 3. Indeed, neutrophils 
of our X-CGD patient could only make NETs and inhibit growth of A. nidulans after genetic 
complementation by GT. Neutrophils expressing functional gp91phox increased from 0% to 
26-29% 6 weeks after GT (Figures 1A-B), then decreased and leveled around 16% for up to 
3 months. The A. nidulans infection completely cleared 6 weeks after GT (Figure 1C), 
correlating with the rise in neutrophils with NADPH oxidase activity. 
Chapter 1 
 30
 
 
Figure 1. Restoration of NADPH oxidase function. (A) Haematopoietic reconstitution and gene marking 
after GT. Absolute neutrophil counts (left y-axis), quantification of gene-modified cells in peripheral 
neutrophils by Q-PCR and quantification of neutrophils with NADPH oxidase activity by DHR test (right y-
axis) are shown. When the percentage of transduced neutrophils decreased, G-CSF (5 μg/KG/day 
subcutaneously) was administered on days + 49 to + 57 and on day + 64. (B) Reconstitution of NADPH 
oxidase activity. Before and 6 weeks after GT gp91phox protein expression was measured by FACS 
analysis after 30 min staining with 10 µg/ml gp91phox-FITC antibody. Superoxide production was assessed 
by oxidation of DHR upon stimulation with PMA and by reduction of NBT to formazan (dark precipitate) 
after stimulation with opsonized zymosan (OPZ). The thresholds were determined using unstained 
(FACS) or unstimulated (DHR) cells for each experiment. (C) PET-CT scan. Before GT, PET-CT scan 
showed several active infectious foci with fluorine-18-fluoro-2-deoxy-D-glucose (FDG) uptake in both 
lungs of the patient (red arrows); infection cleared 6 weeks after administration of gene corrected cells. In 
green, physiologic FDG uptake in heart (arrow), kidneys (arrowheads), bladder (asterisk) and brain 
(diamond) are indicated for reference. 
 
 
The patient’s neutrophils did not make NETs before GT as analyzed by fluorescence 
(not shown), immunofluorescence and scanning electron microscopy (Figures 2A-B and D-E) 
3. After GT, the patient’s neutrophils made NETs (Figures 2C,F), the percentage of cells 
releasing NET-DNA (28%; Figure 2G) correlating with the level of oxidase chimerism (Figure 
1B). Activation of sorted neutrophils showed that reconstitution with functional NADPH 
oxidase allowed corrected CGD neutrophils to make NETs (Figure 2H). 
To test whether efficient eradication of the patient’s infection was due to the 
recovered ability to make NETs, neutrophils were infected with the A. nidulans strain isolated 
from the patient. About 80% of conidia germination (Figure 2I) and 45% of hyphal growth 
(Figure 2J) were inhibited by CGD gp91phox+ neutrophils, comparable to the antimicrobial 
activity of control neutrophils. CGD gp91phox- neutrophils were inefficient in controlling fungal 
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growth (Figure 2I-J, supplemental Figure 1). When NETs were dismantled with MNase 
before infection, fungicidal activity was abrogated to that of CGD gp91phox- neutrophils. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. NET formation and inhibition of A. nidulans growth. Control (A,D), but not CGD (B,E) neutrophils 
made NETs upon 3h PMA stimulation. For immunofluorescence, NETs were stained with an antibody that 
recognizes neutrophil elastase (green; A-C). NETs were clearly visible also by Scanning Electron 
Microscopy (SEM; D-F). Neutrophils isolated from the CGD patient before GT could be activated since 
they flattened out (E), but did not make NETs. The ability to form NETs was partially restored by GT 6 
weeks after GT (C,F white arrows). (G) Quantification of NET-DNA released after 3 h PMA stimulation of 
control neutrophils, CGD neutrophils before and 6 weeks after GT or (H) after stimulation of CGD 
gp91phox+ and CGD gp91phox- FACS sorted neutrophils. CGD gp91phox+ neutrophils showed normal NET 
formation, while CGD gp91phox- neutrophils showed only residual NET formation. FACS-sorting efficiency 
was 90 – 92% for CGD gp91phox− and 95 – 96% for CGD gp91phox+ cells. (I, J) NET inhibition of A. nidulans 
conidia and hyphae. (I) Conidia were plated on FACS-sorted neutrophils pre-stimulated with PMA ± 
MNase i.e. when NET formation was complete, cells were dead and therefore incapable of phagocytosis. 
Hyphal outgrowth was measured after 16 h. (J) Hyphae were co-incubated with FACS-sorted neutrophils 
and PMA ± MNase and hyphal viability was assessed after 5h. The data shown in panels G to J are 
presented as mean ± SD of a representative triplicate experiment. Inhibition of fungal growth is expressed 
as percentage of control values (A. nidulans conidia or hyphae incubated in media). The differences 
between -MNase and +MNase were significant (for control and CGD gp91phox+ cells) by Student’s t-test 
(**P < .01; ***P < .001). 
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In the absence of NETs control of hyphal growth was independent of NADPH oxidase 
activity: when neutrophils were infected after 2h PMA stimulation, before NETs had been 
made, CGD gp91phox+, CGD gp91phox- and neutrophils from healthy donor controlled growth of 
A. nidulans with similar modest efficiency (Figure S2) in a NET-independent fashion, since 
antimicrobial activity was not affected by MNase. This limited NET-independent antimicrobial 
activity, presumably by conidia phagocytosis, degranulation, or unknown mechanisms, 
suggests an NADPH oxidase-independent antifungal mechanism, clinically ineffective before 
GT. These data propose that the patient’s clearance of fungal infection after GT was 
controlled by NETs. Definitive in vivo proof is obviously technically impossible. 
Alveolar macrophages probably constitute the first line of defense to conidia that 
escape mucociliary clearance in healthy individuals 13,16. Whether reconstituted NADPH 
oxidase function in alveolar macrophages also contributed to microbial killing in the patient 
presented is difficult to assess. In neutrophils, however, conidia resist intracellular killing due 
to their relative tolerance to ROS 7,9,12,19-22. Our results suggest that conidia are killed mainly 
extracellularly rather than following phagocytosis. Both conidia and hyphae get ensnared by 
neutrophils and likely killed within NETs by concentrated antimicrobials. Cooperation of 
gp91phox- and gp91phox+ neutrophils in NET antifungal activity is unlikely, since we showed that 
gp91phox- neutrophils do not make NETs when co-incubated with gp91phox+ neutrophils 
(unsorted cells in Figures 2F-G) 10, suggesting that the amount of H2O2 released by gp91phox+ 
neutrophils is insufficient to induce NETs in gp91phox- cells 3. 
A GT approach to treat CGD may be used to overcome recalcitrant, life-threatening 
infections, but is currently limited as salvage therapy to experimental studies in selected 
patients with very poor performance status and lacking a human leukocyte antigen (HLA)-
identical haematopoietic stem cell donor 4. GT was rapidly beneficial to our CGD patient who 
had suffered from an otherwise incurable fungal infection. Until day +86 after GT there was 
no clonal dominance in bone marrow culture derived CD34+ cells (not shown) nor expansion 
of gene-corrected cells in blood (Figure 1A). There is a risk, however, of insertional 
mutagenesis by transactivating retroviral vector insertions into proto-oncogenes as shown in 
a recent GT trial with two adult CGD patients who developed monosomy 7 and 
myelodysplastic syndrome (M. Grez, Institute of Biomedical Research, Georg-Speyer-Haus, 
Frankfurt, Germany, oral communication, April 2009) using the same gammaretroviral 
SF71gp91phox vector 14. Also, five patients developed leukemia in two GT trials in children 
with severe combined immunodeficiency 23,24. These experiences mandate the careful follow-
up of patients. 
In conclusion, we show that the severe immunodeficient phenotype and the high 
susceptibility to Aspergillus infection of CGD patients might be linked to absence of NETs, 
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and that restoration of NADPH oxidase function and NET formation by GT leads to rapid cure 
of refractory invasive aspergillosis in X-linked CGD. 
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Supplemental materials 
 
Patient description and gene therapy 
A 3 y old boy suffered from a severe oxygen-dependent bilateral Aspergillus nidulans lung 
infection, requiring partial resection of the left lower lung lobe. He was diagnosed with X-
linked CGD (CYBB EX1_3del) with complete absence of gp91phox protein expression and 
received prophylaxis with itraconazole and Co-trimoxazole. The infection was non-
responsive to treatment with IV voriconazole, caspofungine, and granulocyte transfusions, 
requiring bone marrow transplantation. There was no human leukocyte antigen (HLA)-
identical sibling or unrelated donor, and his poor clinical condition excluded transplantation 
from an HLA-A disparate donor. 
The boy was treated with gene therapy at age 8 7/12 y with a monocistronic LTR-
driven gammaretroviral SF71gp91phox vector 1 under a protocol approved by the ethics review 
board of the University Children's Hospital Zurich and the Swiss Expert Committee for Bio-
Safety after written informed consent of the parents. Collection of CD34+ cells, transduction, 
conditioning with low-dose liposomal busulfan IV (8.8 mg/KG), and clinical follow up were 
performed as described 1. Treatment with voriconazole was continued throughout and has 
not yet been tapered. 
To increase engraftment rate 2,3, CD34+ cells were transduced twice. The first batch 
(A) was delivered intravenously, the second one (B) by direct intra-osseous injection 6 days 
later. 31% (batch A) and 34.5% (batch B) of the patients CD34 cells expressed gp91 after 
transduction. There were 1.3 (batch A) and 0.96 (batch B) proviral copies per genome. 
Following conditioning, we reinfused 2.2 x106 (batch A) and 3.8 x106 (batch B) 
CD34gp91phox+ cells/KG resulting in a total dose of 6x106 transduced cells/KG. The patient 
experienced a short period of myelosuppression (Figure 1A). Regular follow-up is ongoing. 
 
Methods 
For all NET experiments, neutrophils were resuspended in serum free RPMI media (phenol 
red-free) supplemented with 10mM Hepes and used within 1 h after isolation. The same 
media was used to culture A.nidulans conidia and hyphae. 
Whole body PET-CT was conducted according to standard protocols. For 
immunofluorescence and scanning electron microscopy (SEM) cells were processed as 
described 4. 
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Supplemental figure 1 
 
 
 
 
Figure S1. NET antifungal activity on A. nidulans conidia and hyphae. NET control of A. nidulans conidia 
(panels A-H) and hyphae (panels I-P). Conidia were plated on FACS-sorted neutrophils stimulated with 
PMA for 4 h, i.e. until NET formation was complete, cells were dead and therefore incapable of 
phagocytosis. Hyphae were co-incubated with FACS-sorted neutrophils and PMA. Germination and 
growth of conidia were analyzed after 16 h incubation at 37°C; growth of hyphae after 5 h, revealing NET 
antifungal activity of control (A, I) and CGD gp91phox+ (B, J) neutrophils. This activity was significantly 
reduced after digestion of NETs with Micrococcal Nuclease (MNase) (E, M and F, N). CGD gp91phox- 
neutrophils were inefficient in controlling fungal growth (C, K). A. nidulans growth without addition of 
cells (D-P). A. nidulans survival was visualized as hyphal outgrowth and pictures were taken in parallel to 
the other experiments shown in Figure 2 using an inverted light microscope coupled to a CCD camera. All 
experiments were done at MOI 0.5 (A. nidulans : neutrophils) and were repeated at least three times with 
similar results. 
Chapter 1 
 39
Supplemental figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. NET independent inhibition of A. nidulans hyphal growth. Hyphal outgrowth was measured 
after 16 h pre-incubation of conidia in media. Hyphae were co-incubated with FACS-sorted neutrophils 
and PMA ± MNase and hyphal viability was assessed after 2h (i.e. before NETs formation) at 37°C, 
revealing NADPH oxidase independent growth inhibition during this time. The data shown are presented 
as mean ± SD of a representative triplicate experiment. Inhibition of fungal growth is expressed as 
percentage of control values (A. nidulans hyphae incubated in media). 
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Cover illustration of Blood, 24 September 2009, volume 114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cover caption: It is unclear how neutrophils control Aspergillus species in healthy persons. 
Due to their large size, Aspergillus hyphae (red) cannot be phagocytosed by neutrophils 
(green). Bianchi et al show in this issue that recently discovered NADPH oxidase-dependent 
microbicidal pathways through neutrophil extracellular traps (NETs) are efficient against 
Aspergillus conidia and hyphae in vitro, and that restoration of NET formation by gene 
therapy of NADPH oxidase-deficient X-linked chronic granulomatous disease aided clearing 
severe invasive Aspergillus nidulans infection in vivo, underlining the role of functional 
NADPH oxidase in NET formation and antifungal activity. See the article by Bianchi et al on 
page 2619. 
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Letter sent to Blood regarding the paper: Bianchi M, et al. Restoration of NET formation by 
gene therapy in CGD controls aspergillosis. Blood 2009;114:2619–2622 
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CORRESPONDENCE 
 
To the editor: 
 
We would like to comment on the recent paper by Bianchi andcoworkers.1 Patients 
diagnosed with chronic granulomatous disease (CGD) suffer from recurrent and life-
threatening infections. Analysis of clinical data from 429 European CGD patients recently 
confirmed that Aspergillus is a major threat, causing mostly pneumonia but also brain 
abscesses.2 
Reconstitution of an intact X-linked gene encoding gp91phox is a remarkable 
accomplishment and a promising new therapy for X-CGD. In their Blood paper, Bianchi et al 
correlate the reconstituted nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
activity in this patient with protection against Aspergillus infection, as a result of reconstituted 
neutrophil extracellular trap (NET) formation. NETs are composed of chromatin decorated 
with granular proteins and bind Gram-positive and -negative bacteria, as well as fungi, in a 
nonspecific way. Recently, ex vivo NET formation was shown to depend on superoxide 
production by activated NADPH oxidase.3 The only empirical data provided by Bianchi and 
coauthors to underscore the crucial role of NET formation against Aspergillus infection are ex 
vivo observations showing a microbicidal effect of NETs against Aspergillus species. 
Treating the ex vivo findings as proof of a causal link between (reconstituted) NET 
formation and protection against Aspergillus may be a step too far and may not be essential. 
NETs do not have any specificity in microbicidal activity, whereas CGD patients show a 
selective susceptibility only to certain microbes. 
Moreover, Aspergillus infection has recently been studied in a CGD mouse model, 
and activity of indoleamine 2,3-dioxygenase (IDO) was shown to be crucial for the survival of 
Aspergillus infection.4 IDO converts L-tryptophan into L-kynurenine but requires superoxide 
as a cofactor for its activity. Secreted L-kynurenine subsequently acts as an anti-
inflammatory agent by mechanisms that are incompletely understood but have been shown 
to induce cell death in proinflammatory γδ T-cell subsets producing interleukin-17.4 Romani et 
al thus concluded that hyperinflammation caused a lethal outcome for CGD mice upon 
challenge with Aspergillus, rather than a defective clearance itself, as was previously 
suggested in CGD patients with an overwhelming pulmonary aspergillosis.5 This seems 
plausible in view of a large body of evidence showing that CGD patients often display 
exaggerated immune responses against immunologic challenges,6 and granulomas have 
been shown to develop in the absence of any detectable pathogen, even after wound 
sterilization or after injection of heat-inactivated pathogens.7 
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Romani and coworkers underscore their conclusion by demonstrating that CGD mice, 
which all died upon Aspergillus challenge, survive this infection when treated with the IDO 
product L-kynurenine in combination with interferon-γ. In turn, wild-type mice, which normally 
survive this challenge, no longer overcome Aspergillus infection when treated with the IDO 
inhibitor 1-methyl tryptophan.8 Although the specificity of the challenge and the background 
of the CGD mouse strain are also subject for debate, the abovementioned relevant findings 
were not discussed or referred to in the Bianchi paper. It might be possible that reconstitution 
of other superoxide-dependent steps, such as direct effects or indirectly via IDO activity, 
rather than the restoration of the capability of NET formation, will protect CGD patients from 
Aspergillus infection. 
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CORRESPONDENCE 
 
Response: 
 
We would like to thank Remijsen and colleagues for their comments regarding our recent 
publication in Blood titled "Restoration of NET formation by gene therapy in CGD controls 
aspergillosis."1 
We regret that we neglected to cite the work of Romani et al.2 This was because the 
"Brief Report" format in Blood is restricted in length and number of citations. Romani et al 
reported that superoxide produced by the nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase regulates indoleamine 2,3-dioxygenase (IDO), which leads to L-
kynurenine formation and eventually to the activation of interleukin-17 (IL-17)–producing T 
cells, which are involved in the acquired immune response. Indeed, treatment with L-
kynurenine and interferon-γ helps resolve Aspergillus infections in p47phox-deficient mice, a 
murine model of chronic granulomatous disease (CGD). 
We analyzed the level of L-kynurenine and IL-17 in sera collected from the CGD 
patient described in our publication1 before, as well as 11, 17, and 98 days after, gene 
therapy (GT). There were no significant differences in L-kynurenine levels in the sera before 
and after GT as measured by high-performance liquid chromatography.3 The concentration 
of IL-17 in sera was less than the detection limit of 30 pg/ml of the enzyme-linked 
immunosorbent assay (R&D Systems) at all time points analyzed. Because of ethical 
considerations, we did not analyze local L-kynurenine and IL-17 levels in tissue biopsies, and 
therefore cannot exclude a local effect of the IDO pathway on Aspergillus infection. 
The complex clinical phenotype in CGD patients reflects the pleiotropic functions of 
the NADPH oxidase in immune defense. It is likely that several mechanisms, including the 
activity of IDO, contribute to the restoration of immune defense after GT, and it would 
certainly be important to address this point if the opportunity arises. Treatment with L-
kynurenine, however, has not yet been tested in CGD patients because of concerns about its 
epileptogenic potential. 
The high incidence of aspergillosis compared with other opportunistic infections in 
CGD patients is indeed difficult to explain. It would certainly be interesting to survey how 
neutrophils isolated from these patients respond to a spectrum of different opportunistic 
microbes. Interestingly, knockout mice in any of the NADPH oxidase subunits seem 
susceptible to diverse microbial insults. Regardless, it is clear that the NADPH oxidase, as a 
part of the innate immune system, is initially important in microbe clearance, through, for 
example, phagocytosis and neutrophil extracellular trap (NET) formation. This enzyme, as 
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elegantly shown by Romani et al, is also important in the second function of innate immunity, 
which is to set the stage for an acquired immune response. 
We reported the acquisition of in vitro anti-Aspergillus activity of NETs after GT. This 
is in line with the observations that fungi are more susceptible to NETs than to phagocytic 
killing.4 More importantly, the patient started to get better within few days after engraftment of 
gene-transduced cells, suggesting an immediate innate response. The role of NETs in the 
recovery of the patient will remain a correlation since we reported the in vitro function of 
human cells; in vivo experiments are obviously out of the question. It is likely that the 
improvement after restoration of NADPH oxidase activity in the CGD patient reported was 
due to several pathways where this enzyme is involved. Our data, however, suggest that 
NETs played a prominent role in the clearance of the Aspergillus infection. 
 
Approval was obtained from the ethics review board of the University Children's Hospital 
Zurich and the Swiss Expert Committee for Bio-Safety for these studies. Informed consent 
was provided according to the Declaration of Helsinki. 
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Abstract 
Background: Aspergillus spp infection is a potentially lethal disease in patients with 
neutropenia or impaired neutrophil function. We showed previously that Aspergillus hyphae 
which are too large for neutrophil phagocytosis are inhibited by reactive oxygen species-
dependent neutrophil extracellular trap (NET) formation. This process is defective in chronic 
granulomatous disease (CGD) due to impaired phagocyte nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase function. 
Objective: To determine the antifungal agent and mechanism responsible for reconstitution 
of Aspergillus growth inhibition within NETs after complementation of NADPH oxidase 
function by gene therapy (GT) for CGD. 
Methods: Antifungal activity of free and NET-released calprotectin was assessed by 
incubation of A. nidulans with purified calprotectin, induced NETs from human controls and 
CGD neutrophils after GT in presence or absence of Zn2+ or α-S100A9 antibody, and with 
induced NETs from wild type or S100A9-/- mouse neutrophils. 
Results: We identified the host Zn2+ chelator calprotectin as neutrophil-associated antifungal 
agent expressed within NETs, reversibly preventing A. nidulans growth at low concentration, 
and leading to irreversible fungal starvation at higher concentration. Specific antibody-
blocking and Zn2+ addition abolished calprotectin-mediated inhibition of A. nidulans 
proliferation in vitro. The role of calprotectin in anti-Aspergillus defence was confirmed in 
calprotectin knockout mice. 
Conclusion: Reconstituted NET-formation by GT for human CGD was associated with rapid 
cure of pre-existing therapy refractory invasive pulmonary aspergillosis in vivo, underlining 
the role of functional NADPH oxidase in NET-formation and calprotectin release for 
antifungal activity. These results demonstrate the critical role of calprotectin in human innate 
immune defense to Aspergillus infection. 
 
Capsule Summary 
Susceptibility to Aspergillus infection of patients with CGD might be linked to absence of 
NADPH oxidase-dependent NETs. Restoration of NET-formation and calprotectin-release by 
gene therapy leads to rapid cure of refractory invasive aspergillosis in CGD. 
 
Key Words 
Chronic granulomatous disease, gene Therapy, neutrophil extracellular trap, calprotectin, 
Aspergillus infection. 
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Abbreviations 
CGD: Chronic granulomatous disease 
DAPI: 4’,6-diamidino-2-phenylindole 
GT: Gene therapy 
LTR: Long terminal repeat 
NADPH: Nicotinamide adenine dinucleotide phosphate 
NE: Neutrophil elastase 
NET: Neutrophil extracellular trap 
PMA: Phorbol-12-myristate-13-acetate 
ROS: Reactive oxygen species 
 
Introduction 
Neutrophils kill microbes by distinct reactive oxygen species (ROS) dependent processes: 
intracellularly following phagocytosis and by extracellular mechanisms including neutrophil 
extracellular traps (NETs), which capture and kill bacteria 1, parasites 2 and fungi 3-4. NETs 
are composed of chromatin (histones and DNA), decorated with at least 20 other proteins 1, 4-
5. In naïve neutrophils 8 of these proteins localize to granules, such as neutrophil elastase, 
myeloperoxidase or azurocidin, and 11 to the cytoplasm, such as catalase and the 
calprotectin complex 4. This heteroduplex formed by subunits S100A8 and S100A9 belongs 
to the calcium-binding protein family of S100 proteins, and exerts strong microbistatic activity 
against a variety of microorganims in vitro 6. 
Defective nicotinamide adenine dinucleotide phosphate (NADPH) oxidase function 
accounts for impaired phagocyte ROS production and poor microbial killing in chronic 
granulomatous disease (CGD), leading to recurrent life-threatening bacterial and fungal 
infections. Aspergillus spp infections cause pneumonia and disseminated disease and are 
the leading cause of death in these patients 7-10. ROS production by the NADPH oxidase is 
indispensable for microbe-triggered NET formation 5, 11-12, whilst their mechanism of action in 
this process is unknown. After release from granules neutrophil elastase (NE) and 
myeloperoxidase (MPO) synergize to drive decondensation of chromatin, an early event 
preceding the release of NETs 13-14. ROS might contribute to the release of NE and MPO 
from granules. We previously reported impaired NET-formation in CGD in vitro, resulting in 
defective clearance of Aspergillus infection in vivo. NADPH oxidase-dependent ROS 
production and NET-inhibition of Aspergillus conidia and hyphae were restored early after 
gene therapy (GT) in a patient with X-linked gp91phox (phox, phagocyte oxidase)-deficient 
CGD, paralleled by clearance of therapy refractory Aspergillus nidulans lung infection 11. 
The antifungal agent responsible for A. nidulans growth inhibition within NETs has not 
been characterized. Here we show that amongst the 24 NET associated proteins the major 
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antifungal agent inhibiting Aspergillus growth within NETs is the cytoplasmic calprotectin 
protein complex (S100A8/A9 heteroduplex). This is in good agreement with our previous 
report showing that calprotectin is the major NET component against Candida albicans 4. 
 
Methods 
We treated an 8 7/12 years old boy with X-linked gp91phox-deficient CGD and multifocal 
therapy refractory A. nidulans lung infection with a monocistronic long terminal repeat (LTR)-
driven gammaretroviral SF71gp91phox vector (see reference 11 for details; additional 
information in the “Methods” section in the Online Repository) under a protocol approved by 
the ethics review board of the University Children's Hospital Zurich and the Swiss Expert 
Committee for Bio-Safety after written informed consent of the parents. 
NET induction and quantification 
NET formation was quantified as described 11 after stimulation of 5x104 neutrophils (control, 
CGD unsorted, CGD gp91phox-negative (gp91phox−) and -positive (gp91phox+) sorted 
neutrophils) for 4h with 40nM phorbol-12-myristate-13-acetate (PMA) and staining the NET-
DNA with 1 µM Sytox green (Invitrogen) in a black 96-well plate. Non-stimulated neutrophils 
were used as negative control. The plates were read in a fluorescence microplate reader 
(Victor3, PerkinElmer) with a filter setting of 485/535 nm (excitation/emission). 
A. nidulans growth inhibition 
Antifungal activity of purified calprotectin was assessed incubating
 
A. nidulans conidia or 
hyphae with 0.5-128 µg/ml recombinant S100A8 and S100A9 (ProtEra) ± 1 µM ZnSO4 or 15 
µg/ml rabbit polyclonal α-S100A9 antibody (H00006280-D01P, Abnova). Antifungal activity of 
NETs was determined incubating
 
A. nidulans conidia or hyphae (strain isolated as described 
15 from bronchoalveolar lavage fluid of the patient) with human and murine NETs or human 
NET-extracts ± 0 to 2 µM ZnSO4 or 15 µg/ml rabbit polyclonal α-S100A9 antibody, 
respectively (additional Methods information in the Online Repository). 
NET induction with A. nidulans 
In a 24-well plate, 2x105 control, CGD gp91phox− and gp91phox+ neutrophils were incubated 
with A. nidulans hyphae obtained from culture of 6x104 A. nidulans conidia on polylysine 
coated cover slips for 5 h at 37 °C, then fixed in 4% paraformaldehyde for bright field 
microscopy and immunostaining/confocal microscopy, or 2.5% glutaraldehyde for scanning 
electron microscopy (SEM). For confocal microscopy (SP5, Leica) specimens were blocked 
with 5% donkey serum (Jackson), 1% BSA, 3% cold water fish gelatine (Sigma-Aldrich) and 
0.25% Tween 20 in PBS, incubated with primary antibodies directed against S100A8/A9 
(BM4029 and BM4027, Acris), common Aspergillus spp soluble proteins (NB100-65026, 
Novus Biologicals), and species-specific secondary antibodies coupled to Alexa Fluor 488 
and 568 (Invitrogen). DNA was stained with 4’,6-diamidino-2-phenylindole (DAPI, Sigma-
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Aldrich). For SEM (CM208, Philips), specimens were postfixed with 2% osmium tetroxid, 
dehydrated with graded ethanol series (50 to 100%), critical-point dried, and coated with 10 
nm platinum. 
Release of calprotectin 
In a 96-well plate, 5x104 control, CGD gp91phox− and gp91phox+ neutrophils were stimulated in 
duplicate with 40 nM PMA at 37°C and 5% CO2 for 4 h to form NETs. After 30 min NET 
digestion with 5 U/ml micrococcal nuclease (MNase) + 1 U/ml deoxyribonuclease (DNase)-1 
samples were centrifuged 10 min at 10’000 g to remove debris. Heterodimeric calprotectin 
(S100A8/A9) concentration was measured by ELISA (Hycult, detection limit 1.6 ng/ml) with 
1/10, 1/40 and 1/80 dilutions. As control, total cytoplasmic calprotectin was quantified after 
neutrophil lysis. 
 
Results 
NET quantification in CGD neutrophils after GT 
We aimed to identify factors that limit A. nidulans growth in NADPH oxidase-dependent 
NETs. Therefore we first analyzed whether NET-formation was restored 2.6 years after GT in 
gp91phox+ (transduced) compared to gp91phox− (non-transduced) neutrophils from the reported 
CGD patient 11. Staining with α-gp91phox antibody showed 22.8% gp91phox+ neutrophils. 
Sorting of gp91phox− and gp91phox+ neutrophils by autoMACS (Miltenyi Biotec) resulted in 
purity of 98.3% and 92.5% (Fig 1, A). 
 
 
 
 
 
 
 
 
 
FIG 1. NET quantification in CGD gp91phox+ and gp91phox− 
sorted neutrophils. A, Neutrophils were sorted by 
magnetic beads and autoMACS. B, NET-formation was 
quantified after PMA activation of neutrophils, by 
staining of released NET-DNA with Sytox green. Data 
are mean ± SD of representative triplicate experiments. 
Difference between control and gp91phox+ neutrophils 
was non-significant (P > 0.05). 
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Quantification of NET-formation in CGD neutrophils after GT correlated well with the 
percentage of gp91phox+ cells, 20.5% of unsorted, 3.2% of gp91phox−, and 87.6% of gp91phox+ 
neutrophils releasing NETs (Fig 1, B). The O2- production of individual gp91phox+ neutrophils 
was 27.8% (compared to control), measured by reduction of cytochrome c (data not shown) 
16, indicating this threshold as enough for substantial, albeit not 100% NET-formation. 
Calprotectin inhibits A. nidulans growth efficiently 
We previously identified the cytoplasmic protein complex calprotectin as major antifungal 
effector in NETs preventing growth of C. albicans 4 and therefore reasoned that calprotectin 
might also be responsible for NET-mediated growth inhibition of A. nidulans. There is 
currently no information available whether purified calprotectin is able to inhibit Aspergillus 
spp. To evaluate the inhibitory activity of each calprotectin subunit on A. nidulans growth, we 
incubated conidia and hyphae with purified subunits S100A8 and S100A9 17. Addition of 
S100A8 did not inhibit fungal growth, whereas S100A9 had a small effect on conidia 
germination, but not on hyphae growth (Fig 2, A-B and E1 in the Online Repository). Only 
both subunits together strongly inhibited A. nidulans growth, indicating that the heteroduplex 
is required for full inhibition of Aspergillus spp, consistent with a report on its anti-candidal 
activity 18. In all cases, addition of 1 µM zinc (Zn2+) restored fungal growth, confirming the 
putative role of Zn2+ chelation by calprotectin in suppressing fungal growth 18-20. 
 
 
 
FIG 2. Inhibition of A. nidulans growth by purified calprotectin. A-B, Conidia and hyphae incubated with 5 
µg/ml S100A8 and/or S100A9 ± 1 µM Zn2+. C-D, Conidia and hyphae incubated with 5 µg/ml S100A8 and 
S100A9 ± 15 µg/ml polyclonal α-S100A9 antibody or unspecific control antibody. Data are mean ± SD of 
representative triplicate experiments. 
 
Additionally, we pre-incubated combined S100A9 and S100A8 with a polyclonal α-S100A9 
antibody. A. nidulans growth of conidia and hyphae was restored in the presence of specific 
antibody (Fig 2, C-D and E2), confirming the requirement for interaction of both calprotectin 
subunits for antifungal activity. Unspecific control antibody did not have any effect. Here we 
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used an excess amount of 5 µg/ml purified S100A8 and S100A9, but similar inhibitory effects 
were obtained with as low as 0.5 µg/ml, a calprotectin amount found in NETs from about 4 
million neutrophils 4. 
Antifungal activity of CGD gp91phox+ cells is calprotectin dependent 
To study whether restored antifungal activity of CGD gp91phox+ neutrophils after GT was 
attributable to calprotectin, we PMA-stimulated gp91phox+ and gp91phox− neutrophils to induce 
NETs, and coincubated with A. nidulans conidia and hyphae ± Zn2+. Only gp91phox+ 
neutrophils showed strong antifungal activity, equivalent to control (Fig 3, A-B and E3). 
gp91phox− neutrophils did not form NETs (Fig 1, B), yet partially inhibited conidia germination, 
probably by phagocytosis 21, but were inefficient against hyphae. Full restoration of A. 
nidulans growth by addition of Zn2+ supports the assumption that NET antifungal activity was 
calprotectin dependent (at calprotectin concentrations of 450-500 ng/ml, measured by 
ELISA). 
 
 
 
FIG 3. Calprotectin dependent antifungal activity of CGD gp91phox+ neutrophils. A. nidulans conidia or 
hyphae incubated with NETs (A-B) or NET-supernatant (C-D) from control and CGD sorted neutrophils ± 1 
µM Zn2+ or 15 µg/ml α-S100A9, respectively. E, Wild type and S100A9-/- mouse NETs infected with A. 
nidulans conidia or hyphae. Data are mean ± SD of representative triplicate experiments. 
 
Restoration of A. nidulans conidia and hyphae growth by Zn2+ addition was dose 
dependent (Fig E4). Addition of Mn2+, Fe2+ and Cu2+ (0 to 2.5 µM) however, did not restore 
fungal growth (not shown); indicating that Zn2+ binding by calprotectin has a major NET anti-
Aspergillus activity. Since addition of metal ions can have pleiotropic effects, we applied an 
α-S100A9 antibody to block calprotectin-mediated inhibition in concentrated NET-extracts, 
subsequently incubated with A. nidulans conidia or hyphae. NET-extracts from gp91phox+ 
neutrophils in presence of unspecific control antibody showed strong antifungal activity, 
similar to control (Fig 3, C-D and E5). Supernatants from non-NET forming gp91phox− 
neutrophils in presence of unspecific control antibody did not have antifungal activity, even 
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against conidia germination, supporting the hypothesis that their low antifungal activity 
observed against conidia (Fig 3, A) was due to phagocytosis. 
We then tested if NET-mediated A. nidulans inhibition was calprotectin dependent 
comparing wild-type and calprotectin-deficient mouse neutrophils. NETs were PMA-induced 
in mature neutrophils from both mouse strains and incubated with A. nidulans conidia and 
hyphae. Indeed, NETs from calprotectin-deficient neutrophils did not prevent A. nidulans 
growth, whereas NETs from wild-type neutrophils did (Fig 3, E), although the amount of NET-
formation was similar in calprotectin-deficient and wild-type neutrophils 4. Complete 
restoration of fungal growth in presence of α-S100A9 antibody in human gp91phox+ and 
control NET-extracts and the inability of calprotectin-deficient murine NETs to block fungal 
growth confirmed the essential antifungal role of NET-associated calprotectin against A. 
nidulans. 
Antifungal effect of calprotectin 
To determine whether calprotectin-mediated inhibition of A. nidulans growth within NETs was 
reversible or irreversible we incubated conidia and hyphae on NETs for 4 days to 4 weeks at 
neutral pH, then added Zn2+ to restore fungal growth. NETs strongly inhibited A. nidulans 
conidia germination and hyphae growth even after 4 weeks (Fig 4, A-P), indicating strong 
stability of calprotectin/Zn2+ complexes, agreeing well with their reported stability against 
proteases 22. Surprisingly, addition of Zn2+ restored fungal growth even after 4 weeks, 
demonstrating that calprotectin has fungistatic, but not fungicidal activity on A. nidulans at 
low concentrations (450-500 ng/ml, measured by ELISA). 
We next tested whether antifungal activity was still reversible at higher calprotectin 
concentrations which might occur in vivo. We incubated conidia and hyphae for 4 days with 
increasing concentrations of purified calprotectin S100A8 and S100A9, then added Zn2+ to 
restore fungal growth. Conidia germination was inhibited at any concentration (Fig 4, Q, 
white bars) whereas hyphae were slightly more resistant showing a dose-dependent 
increase of growth arrest between 0.5 and 4 µg/ml of S100A8/A9 (Fig 4, R, white bars). 
Fungal growth was not restored by Zn2+ when S100A8/A9 concentration was higher than 16 
µg/ml (Fig 4, Q-R, black bars). Light microscopy showed intact hyphae at low S100A8/A9 
concentrations (Fig 4, S), whereas in presence of >16 µg/ml S100A8/A9 hyphae had a 
translucent cell wall and a fragmented internal structure (Fig 4, T). Thus, we demonstrate a 
previously unknown microbicidal effect against A. nidulans at high calprotectin 
concentrations. 
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FIG 4. Antifungal effect of calprotectin. A-P, Fungistatic activity: A. nidulans conidia or hyphae incubated 
with NETs for 4 days to 4 weeks, after which 1 µM Zn2+ was added overnight. Q-R, Fungicidal activity: A. 
nidulans conidia or hyphae incubated with 0.5 (S) to 128 (T) µg/ml purified S100A8/A9 for 4 days, after 
which 50 µM Zn2+ was added overnight. 
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A. nidulans-induced NET-formation is strictly dependent on NADPH oxidase 
We investigated whether the induction of NETs by A. nidulans is dependent on functional 
NADPH oxidase and is restored after CGD GT. CGD gp91phox+ and gp91phox− neutrophils 
were incubated with A. nidulans hyphae and observed for NET-formation by light 
microscopy, SEM, and by immunostaining with confocal microscopy. Hyphae induced NETs 
in control and gp91phox+ neutrophils but, as expected, less strongly compared to PMA 
stimulation. We observed that NET formation mainly occurred when neutrophils were in 
direct contact with hyphae (Fig 5, A-B, black arrows). This might suggest that close 
pathogen-neutrophil interaction promotes induction of NETs. The molecular details behind 
this trigger mechanism will be subject to further investigation. In contrast, gp91phox− 
neutrophils did not form NETs when in contact with hyphae (Fig 5, C, white arrowheads), 
underlining the role of functional NADPH oxidase in NET-formation and antifungal defense. 
Analysis by SEM showed that A. nidulans hyphae were entangled by NETs from control and 
gp91phox+ neutrophils (Fig 5, D, G and E, H), whereas gp91phox− neutrophils surrounded and 
wrapped around hyphae but did not make NETs (Fig 5, F, I). 
Calprotectin is NET-associated after A. nidulans incubation 
The association of calprotectin and A. nidulans-induced NETs was studied by 
immunofluorescence and confocal microscopy, staining DNA with DAPI and calprotectin and 
hyphae with primary antibodies. Colocalization of DNA (blue) and calprotectin (red) 
demonstrates that calprotectin was released and associated with NETs when control (Fig 5, 
J, M, P) and gp91phox+ (Fig 5, K, N, Q) neutrophils were incubated with A. nidulans hyphae 
(green). Moreover, we demonstrate that gp91phox− neutrophils neither showed NET-formation 
nor extracellular calprotectin upon A. nidulans incubation (Fig 5, L, O, R), although they were 
able to recognize A. nidulans, as judged by migration towards and wrapping around hyphae 
(Fig 5, R). DNA was confined to the nucleus (Fig 5, L) and calprotectin to the cytoplasmic 
compartment of these cells (Fig 5, O).  
Notably, the quantification of calprotectin by ELISA confirmed our microscopical 
findings. Control, gp91phox+ and gp91phox− neutrophils were activated with PMA for 4h and 
calprotectin release was determined by ELISA after NET-formation and subsequent digestion 
of NETs. Control and gp91phox+ neutrophils released approximately four times the calprotectin 
concentration compared to gp91phox− neutrophils (Fig 6), supporting the previous results. 
Differences in total cytoplasmic calprotectin concentration between control, gp91phox+ and 
gp91phox− neutrophils were not statistically significant (data not shown). Thus, we conclude 
that NADPH oxidase is not only required for the release of NETs but also for the release of 
calprotectin, the crucial component for the inhibition of A. nidulans hyphae. 
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FIG 5. A. nidulans induced NETs contain calprotectin. Control and CGD sorted neutrophils were infected 
with hyphae and NET-formation was determined by bright field microscopy (A-C), SEM (D-I), and 
immunofluorescence and confocal microscopy (J-R). NET-formation was determined by DAPI (blue), 
calprotectin by staining with antibodies against S100A8/A9 (red) and hyphae with antibodies against 
Aspergillus soluble proteins (green). 
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FIG 6. Calprotectin release by gp91phox+ and gp91phox− neutrophils. Calprotectin 
release was quantified by ELISA after neutrophil activation by PMA inducing NET-
formation. NETs were digested by MNase/DNase-1 to quantify NET-associated 
calprotectin. Significance was assessed by Student’s t-test: N.S. = not significant 
(P > 0.05), ***P < 0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
Recent work suggests NET contribution to elimination of fungal infections in healthy subjects 
since hyphae are too large to be phagocytosed 23-24. CGD patients are unable to make NETs 
5, 11 and are susceptible to therapy-refractory infection with Aspergillus spp 10. Especially 
infections with A. nidulans are a major threat to these patients, due to higher virulence and 
frequent resistance to antifungal treatment, as compared to A. fumigatus 7. Here we show 
that genetic complementation of NADPH oxidase by human CGD GT restored the ability of 
neutrophils to release NETs and NET-associated calprotectin, which is responsible for 
growth inhibition of A. nidulans by Zn2+ sequestration. A threshold of 27.8% of O2- production 
per individual gp91phox+ neutrophil and a chimerism of 22.8% of oxidase-positive cells was 
enough for sufficient NET-formation in vitro and clinical clearance of multifocal therapy-
refractory A. nidulans lung infection in a patient with CGD in vivo. 
The S100 Ca2+-binding protein calprotectin is a heteroduplex of subunits S100A8 and 
S100A9 which is expressed by granulocytes, monocytes, and early differentiation stages of 
macrophages 25. It represents about 40 % of neutrophil cytoplasm 26, accumulates at high 
concentrations (1-20 mg/ml) in abscess-fluid supernatants 27 and has been shown to bind 
Zn2+ in vitro 28. Its growth inhibitory effect on fungi is most likely mediated by metal-chelation 
and is reversible by micro-molar quantities of Zn2+ 18, 27-28. We set out to study the role of 
calprotectin in innate defense against CGD relevant A. nidulans. Growth of A. nidulans was 
strongly inhibited when coincubated with both purified calprotectin subunits, which is in 
accordance with a report by Sohnle et al 17 and with crystal structure 29 as well as mass 
spectrometric analyses 30 suggesting that the Ca2+-dependent formation of S100A8/A9 
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heterotetramers would lead to enhanced Zn2+-binding capacity, whilst none of the 
homodimers should display significant affinity for Zn2+ 29.  
Our study demonstrates the major role of NET-associated calprotectin in suppressing 
growth of A. nidulans conidia and hyphae, and shows presence of calprotectin in NETs 
induced by A. nidulans hyphae. A. fumigatus has been reported recently to trigger NET 
release 31-32, resulting in growth inhibition of A. fumigatus which could be prevented by Zn2+ 
32. However, the mechanism of inhibition was not clearly shown in these reports. Here we 
show that blocking of calprotectin by specific antibodies and the absence of calprotectin in 
NETs from calprotectin-deficient mouse neutrophils completely abrogated the inhibition of A. 
nidulans conidia and hyphae growth. This is a more precise analysis, since NETs also 
contain other Zn2+ binding proteins, such as S100A12 33 which is involved in anti-parasite 
responses.  
According to our findings calprotectin has to be presented extracellularly for antifungal 
activity against A. nidulans. To the best of our knowledge, leakage of a cytoplasmic protein 
into phagolysosomes has not been described. We previously showed that neutrophil 
degranulation stimulated by the bacterial peptide fMLP does not induce secretion of 
calprotectin, indicating non-vesicular localization 4. However, we cannot entirely exclude that 
minor amounts of calprotectin are found in phagolysosomes and contribute to the slight 
inhibitory effect we reported on CGD neutrophils infected with A. nidulans conidia.  
We show that presence of functional NADPH oxidase in human neutrophils is an 
absolute requirement for A. nidulans growth inhibition by NET-associated calprotectin, as 
only gp91phox+ but not gp91phox− neutrophils made NETs containing calprotectin and inhibited 
A. nidulans growth efficiently. GT of human CGD restored the amount of released 
calprotectin during NET-formation to wild-type levels and NET-associated calprotectin co-
localized with A. nidulans hyphae. Analysis of gp91phox− neutrophils enabled us to establish 
the role of NADPH oxidase for the release of calprotectin during NET formation, which is an 
advantage over chemical inhibition of NADPH oxidase using diphenylene iodonium chloride 
(DPI). We propose that NET formation is an NADPH oxidase-dependent mechanism by 
which neutrophils secrete calprotectin into the extracellular compartment upon infection with 
Aspergillus hyphae, resulting in both NET-bound and free calprotectin. NET-associated 
calprotectin is concentrated with trapped Aspergillus for antifungal function. Unbound 
calprotectin may additionally serve for distinct functions, such as chemotaxis or inflammation.  
The fact that gp91phox− neutrophils also partially inhibited conidia germination, 
suggests that NADPH oxidase-independent mechanisms linked to phagocytosis, such as 
activity of the granule serine proteases NE and cathepsin G 34-36 (while the mechanism has 
been recently object of controversy 37-39), might contribute to early defense against 
Aspergillus. The need of NE for NET formation 14 could explain the susceptibility to infection 
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of NE deficient mice described by Revees et al 35 as an indirect action. Other mechanisms 
such as the tryptophan catabolizing enzyme indoleamine-2,3-dioxygenase (IDO), considered 
critical for regulating immune responses and suppression of inflammation in mice 40, do not 
play a role in human CGD as we previously reported 41-42.  
Fungi have high Zn2+ requirement (10-7-10-5 M) for growth 43 with a low minimum 
inhibitory concentration of calprotectin 44. Due to the lack of a well-developed extracellular 
Zn2+-scavenging system, A. fumigatus is extremely sensitive to Zn2+ deprivation 45. Zn2+ 
requirement for A. nidulans in our study was in the same range as described for other fungi. 
In contrast to S. aureus which is more sensitive to calprotectin-mediated Mn2+ deprivation 19, 
we found that A. nidulans could only resume growth after Zn2+ supplementation, but not after 
Mn2+, Fe2+ or Cu2+ addition. This supports the central role of Zn2+ for A. nidulans growth. 
Interestingly, A. nidulans hyphae were not killed by NETs at low calprotectin 
concentrations in vitro, although hyphal structures seemed to be severely deranged by 
NETs. This corresponded to the range of fungistatic calprotectin concentrations described for 
Candida 44. A. nidulans growth was restored after addition of Zn2+, even after a month of 
inhibition by NETs. As much higher calprotectin concentrations have been observed in 
human abscesses 27, Aspergillus hyphae might still be killed by NET-associated calprotectin 
in vivo. Killing of Candida spp. or Cryptococcus neoformans was demonstrated at 
calprotectin concentrations of 3-5 µg/ml 44. We show for the first time that calprotectin 
concentrations ≥ 16µg/ml lead to irreversible growth arrest of A. nidulans conidia and 
hyphae, most likely by Zn2+ starvation. In contrast to our findings a previous publication 
reported only minor antifungal activity of NETs against A. fumigatus 31, probably due to a 
shorter incubation period. Alternatively, complete in vivo killing might also be achieved by 
other antimicrobial peptides 46 or by so far unknown mechanisms: in addition to their 
antimicrobial properties, S100A8, S100A9, and S100A8/A9 are chemotactic for neutrophils 
and monocytes 47-49. Notably, for this function calprotectin needs to be extracellular, and thus 
Aspergillus-induced NET formation supports it as well. 
Here we establish that calprotectin released in NETs displays concentration-
dependent reversible and irreversible growth inhibitory activity against virulent A. nidulans. 
NETs may be involved in disarming A. nidulans and may prevent further spreading by 
providing high local concentrations of calprotectin. Definitive in vivo proof in humans is 
obviously ethically impossible. In conclusion, we show that calprotectin is a critical factor in 
the innate immune defense of human neutrophils to Aspergillus infection and adds to the 
concept of metal chelation as a strategy for inhibiting microbial growth at the sites of 
infection. The severe immunodeficient phenotype and the high susceptibility to Aspergillus 
infection of CGD patients might be linked to absence of NETs, and restoration of NADPH 
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oxidase function and NET-formation by GT leads to rapid cure of refractory invasive 
aspergillosis in X-linked CGD. 
 
Clinical implications 
Gene therapy for CGD restores NET-formation and calprotectin release by neutrophils, 
leading to efficient A. nidulans inhibition. Calprotectin is a critical factor in human innate 
immune defense against Aspergillus infection. 
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Methods 
Patient description and gene therapy (GT) 
We treated an 8 7/12 years old boy with X-linked gp91phox-deficient CGD and multifocal 
therapy refractory A. nidulans lung infection with a monocistronic LTR-driven 
gammaretroviral SF71gp91phox vector (details in 1) under a protocol approved by the ethics 
review board of the University Children's Hospital Zurich and the Swiss Expert Committee for 
Bio-Safety after written informed consent of the parents. Collection of CD34+ cells, 
transduction, conditioning with low-dose busulfan IV (8.8 mg/KG), and clinical follow up were 
performed as described 2. The A. nidulans lung infection was completely cleared six weeks 
after GT. Therapy/prophylaxis with oral voriconazole was continued throughout and has not 
yet been tapered 2.6 years after GT. To avoid interactions, voriconazole was stopped four 
days prior to Aspergillus experiments and continued thereafter. At time of analysis the patient 
was free of any infection, 22.8% of neutrophils expressed gp91phox, with an O2− production of 
27.8% per gp91phox expressing cell (relative to healthy controls) 3. Clinical and molecular 
follow-up of GT in this patient will be described elsewhere. 
Aspergillus nidulans strain 
The A. nidulans strain used was isolated from bronchoalveolar lavage fluid of the patient; 
conidia were grown and collected as described 4. For all experiments conidia and hyphae 
were grown in serum free RPMI medium (phenol red-free) supplemented with 10 mM Hepes. 
If not stated otherwise, fungal growth was quantified in all assays with the tetrazolium dye 
2,3-bis(2-Methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT, Invitrogen) as 
described 5. This method, unlike colony forming unit (CFU) enumeration, does not require 
dispersion of the hyphae. 
Isolation of human and murine neutrophils 
Human neutrophils were isolated from peripheral blood of healthy donors or the CGD patient 
using dextran-Ficoll (GE Healthcare) 6 for all NET assays with A. nidulans and for autoMACS 
sorting, whereas Percoll (GE Healthcare) density gradient separation 7 was used for NET 
quantification assays. For all experiments, neutrophils were resuspended in serum free RPMI 
medium (phenol red-free) supplemented with 10 mM Hepes and used within 1 hour after 
isolation.  
Murine neutrophils were isolated from S100A9−/− mice backcrossed 10 times into C57 
BL/6. These mice are deficient in both calprotectin subunits S100A8 and S100A9 protein 8. 
Mice were bred in our animal facility according to regulations of the Jordbruksverket Sweden 
(Dnr A29-69). Mature murine neutrophils were isolated from bone marrow as previously 
described 9. Briefly, bone marrow cells from tibia and femur were singularized using a 70 µm 
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cell strainer and separated by centrifugation for 30 min at 1,500 g on a discontinuous Percoll 
gradient with 52 % (v/v), 69 % (v/v), and 78 % (v/v). Neutrophils harvested from the distinct 
layer between 69 % and 78 % were resuspended in HBSS without Ca2+ and Mg2+. 
Sorting of CGD gp91phox+ and gp91phox− neutrophils 
Control and patient neutrophils were first stained 30 min at room temperature with 10 µg/ml 
mouse α- gp91phox-FITC antibody (clone 7D5, MBL), then 30 min at 4°C with anti-FITC 
MicroBeads (Miltenyi Biotec) for magnetic separation by autoMACS (Miltenyi Biotec), 
according to the manufacturer’s instructions. Purity of resulting gp91phox-negative (gp91phox−) 
and -positive (gp91phox+) populations was directly measured by the fluorescent-activated cell 
sorter (FACS). 
A. nidulans growth inhibition by purified calprotectin 
In a 96-well plate, 104 A. nidulans conidia or hyphae obtained from culture of 104 conidia 
were incubated 24 h at 37°C with 5 µg/ml recombinant S100A8 and/or 5 µg/ml recombinant 
S100A9 (ProtEra) ± 1 µM ZnSO4 or 15 µg/ml rabbit polyclonal α-S100A9 antibody 
(H00006280-D01P, Abnova) vs. unspecific control antibody (Sigma-Aldrich) 10. This α-
S100A9 antibody recognizes the whole S100A9 subunit alone or the S100A9 subunit 
complexed with S100A8. Fungal growth is expressed as percentage of control values (A. 
nidulans conidia or hyphae incubated in media without neutrophils ± ZnSO4, S100A8/A9 or 
antibodies). 
A. nidulans growth inhibition by NETs 
In a 96-well plate, 105 control, CGD gp91phox− and gp91phox+ sorted neutrophils were activated 
with 40 nM PMA (Sigma-Aldrich) at 37°C and 5% CO2 for 4 h, until NET formation was 
complete. 0 to 2 µM ZnSO4 (Sigma-Aldrich) and A. nidulans conidia or hyphae (hyphae 
previously grown O/N in a 24-well plate, collected by pipetting and scraping the wells with a 
cell scraper) with a multiplicity of infection (MOI) A. nidulans/neutrophils of 0.1 were then 
added, in a final volume of 160 µl. Afterwards the plates were centrifuged 5 min at 400 g and 
incubated 24 h at 37°C, allowing conidia germination and hyphal outgrowth. Fungal growth is 
expressed as percentage of control values (A. nidulans conidia or hyphae incubated in media 
± ZnSO4). 
A. nidulans growth inhibition by NET-extracts 
NET formation was induced in 8x105 control, CGD gp91phox− and gp91phox+ neutrophils by 
activation with 40 nM PMA at 37°C and 5% CO2 for 5 h in a 24-well plate (500 µl/well; 4 wells 
each; 3.2x106 cells total). For maximal DNA fragmentation NETs were then digested for 30 
min with 5 U/ml micrococcal nuclease (MNase, Worthington Biochemical) + 1 U/ml 
deoxyribonuclease (DNase)-1 (Sigma-Aldrich), and pooled supernatant concentrated ~ 10-
fold by centrifugation on filter columns with 3 kDa cut-off (Amicon, Millipore), following the 
manufacturer’s instructions. In a 96-well plate, 104 A. nidulans conidia or hyphae obtained 
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from culture of 6x104 A. nidulans conidia were then incubated 24 h at 37°C with the 
concentrated NET-extracts (diluted 1/3) with or without 15 µg/ml α-S100A9 or unspecific 
control antibody in 100 µl final volume. Fungal growth is expressed as percentage of control 
values (A. nidulans conidia or hyphae incubated in media ± antibodies). 
A. nidulans growth inhibition by murine S100A9−/− NETs 
In a 24-well plate, 5x105 mouse neutrophils in 500 µl RPMI with 1% (v/v) mouse serum were 
stimulated with 100 nM PMA for 20 h at 37°C with 5% CO2 to induce NET formation. The 
supernatant was discarded; NETs were washed once with RPMI and incubated with 500 µl 
RPMI containing A. nidulans conidia or hyphae at MOI 0.1 and 0.01, respectively. Afterwards 
plates were centrifuged for 5 min at 300 g and incubated 20 h at 37°C. Fungal growth is 
expressed as percentage of control values (A. nidulans conidia or hyphae incubated in 
media). 
Fungistatic and fungicidal effect of calprotectin 
In a 96-well plate, 104 A. nidulans conidia or hyphae obtained from culture of 104 conidia 
were incubated on previously formed NETs (from 105 neutrophils activated with 40 nM PMA 
at 37°C and 5% CO2 for 4 h) or with 0.5-128 µg/ml purified S100A8/A9. After 4 days to 4 
weeks, RPMI or ZnSO4 (final concentration 1 µM for NETs and 50 µM for purified 
S100A8/A9) were added to the wells and incubated O/N. Growth of A. nidulans conidia or 
hyphae was assessed using an inverted light microscope (Leica DM IL HC Fluo) coupled to a 
CCD camera (Leica DFC 480 R2).  
Statistical analysis 
Two-tailed Student’s t-test was used for analysis of two groups. Differences were considered 
statistically significant when p < 0.05. All statistical tests were performed using GraphPad 
Prism. 
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Figure E1 
 
 
 
 
 
FIG E1. Inhibition of A. nidulans growth by purified calprotectin is abolished by Zn2+ addition. Incubation 
with the S100A8 (5 μg/ml) subunit did not prevent A. nidulans conidia or hyphae growth, whereas 
incubation with S100A9 (5 μg/ml) partially inhibited conidia germination. Coincubation with both subunits 
strongly inhibited conidia germination and hyphae growth. In all cases, antifungal activity was completely 
abolished in presence of 1 μM Zn2+. 
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Figure E2 
 
 
 
 
 
FIG E2. Inhibition of A. nidulans growth by purified calprotectin is abolished by α-S100A9 antibody. 15 
μg/ml polyclonal α-S100A9 antibody fully inhibited antifungal activity of the S100A8/A9 calprotectin 
complex on conidia or hyphae. As control, S100A8/A9 was incubated with an unspecific control antibody, 
showing no effect on antifungal activity of the S100A8/A9 calprotectin complex. w/o, without. 
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Figure E3 
 
 
 
 
 
FIG E3. Calprotectin-dependent antifungal activity of CGD gp91phox+ neutrophils is abolished by Zn2+ 
addition. Control and CGD sorted neutrophils were stimulated with PMA for NET formation and incubated 
overnight with A. nidulans conidia or hyphae in presence or absence of 1 μM Zn2+. gp91phox+ neutrophils 
showed strong antifungal activity against conidia or hyphae, comparable to control. gp91phox− neutrophils 
were inefficient in controlling fungal growth, with only partial inhibition of conidia germination. In all 
cases, antifungal activity was completely abolished in presence of 1 μM Zn2+. 
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Figure E4 
 
 
 
 
 
FIG E4. NET-inhibition of A. nidulans growth is abolished by Zn2+ addition. Human neutrophils were 
stimulated with PMA for NET formation and subsequently infected overnight with A. nidulans conidia or 
hyphae ± Zn2+. Increasing concentrations of Zn2+ abolished the antifungal activity of NETs against conidia 
(A) or hyphae (B). (C) Representative pictures of data shown in (A-B). 
 
 
 
 
A 
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Figure E5 
 
 
 
 
 
FIG E5. Calprotectin-dependent antifungal activity of CGD gp91phox+ neutrophils is abolished by α-S100A9 
antibody. Control and CGD sorted neutrophils were stimulated with PMA for NET formation; NET 
supernatant was digested by DNase/MNase, concentrated and incubated with A. nidulans conidia or 
hyphae after previous incubation with 15 μg/ml polyclonal α-S100A9 or unspecific control antibody. NET 
extracts from control and gp91phox+ neutrophils showed strong antifungal activity against conidia or 
hyphae. Supernatant from gp91phox− neutrophils had no inhibitory activity on fungal growth. In all cases, 
fungal growth was completely restored by addition of α-S100A9 antibody proving that the restored 
antifungal activity of gp91phox+ neutrophils after GT was calprotectin dependent. 
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Letter sent to JACI regarding the paper: Bianchi M, et al. Restoration of anti-Aspergillus 
defense by neutrophil extracellular traps in human chronic granulomatous disease after gene 
therapy is calprotectin-dependent. J Allergy Clin Immunol 2011; online June 20 
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CORRESPONDENCE 
 
Redundant ability of phagocytes to kill Aspergillus species 
To the Editor: 
Recently, Bianchi et al1 published an excellent article demonstrating the efficacy of 
neutrophil extracellular traps (NETs) in killing Aspergillus nidulans. The authors show that 
this killing is mediated by calprotectin associated with NETs. Neutrophils cannot phagocytose 
long Aspergillus hyphae, but they can form NETs along such hyphae and thereby effectively 
destroy these fungal structures. In contrast, neutrophils from patients with chronic 
granulomatous disease (CGD) are unable to form NETs because NET formation depends on 
the production of reactive oxygen species (ROS). ROS are normally produced by the 
multienzyme complex nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, which 
is defective in CGD. Furthermore, CGD neutrophils are highly impaired in killing Aspergillus 
species and Aspergillus infections, especially with A. nidulans, consistently remain the most 
frequent cause of death in CGD. In addition, reconstitution of the NADPH oxidase by gene 
transfer restores NET formation and killing of Aspergillus species. 
On the basis of all these findings, the authors suggest that the inability of CGD 
neutrophils to form NETs is the main reason for Aspergillus infections in patients with CGD 1. 
However, the observation that completely myeloperoxidase (MPO)-deficient patients 
normally do not suffer from Aspergillus infections challenges this conclusion 2. Completely 
MPO deficient neutrophils are also entirely unable to form NETs at least when stimulated 
with PMA or Candida species. 3. Normally, MPO further metabolizes ROS produced by the 
NADPH oxidase to form different kinds of ROS such as hypochlorous acid. Whether such 
MPO metabolites or another ROS/MPO dependent mechanism is ultimately necessary for 
NET formation remains unknown. So far, data suggest that it is not the NADPH oxidase, but 
an MPO-dependent downstream event that triggers NET formation 3. 
MPO deficiency is relatively frequent (1 in 2000-4000 in Europe and the United 
States), and complete MPO deficiency represents a considerable portion of these 2. 
Therefore, complete MPO deficiency is much more frequent than CGD (∼ 1 in 200,000 
births). Candida albicans infections are somewhat more common in patients with MPO 
deficiency than in the normal population especially when additional influences such as 
diabetes contribute to susceptibility. However, according to the information available, 
susceptibility to Aspergillus species, in an order of magnitude comparable to CGD, can be 
excluded in patients who are completely deficient in MPO despite the inability of their 
neutrophils to form NETs. 
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It is very unlikely that completely MPO-deficient neutrophils form NETs only when 
stimulated with Aspergillus species, but not when stimulated with PMA or Candida species. 
In one study, MPO-deficient neutrophils even failed to damage A fumigatus hyphae in vitro 4. 
However, mice with MPO deficiency showed only a slightly delayed clearance of A. 
fumigatus from the lungs 5. In contrast, mice with CGD survived Aspergillus infections only 
for a short time 6. Therefore, mammalian neutrophils and/or other phagocytes have most 
likely redundant abilities to kill Aspergillus species that are all ROS-dependent and therefore 
defective in CGD. However, details remain to be elucidated by appropriate experiments. 
 
Disclosure of potential conflict of interest: the authors have declared that they have no 
conflict of interest. 
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myeloperoxidase. J Infect Dis 2000; 182(4):1276-9. 
6 Aratani Y, Kura F, Watanabe H, Akagawa H, Takano Y, Suzuki K et al. Relative 
contributions of myeloperoxidase and NADPH-oxidase to the early host defense 
against pulmonary infections with Candida albicans and Aspergillus fumigatus. Med 
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CORRESPONDENCE 
 
Reply 
To the Editor: 
We thank Roesler and Rösen-Wolff for their comments1 regarding our recent 
publication titled ‘‘Restoration of anti-Aspergillus defense by neutrophil extracellular traps in 
human chronic granulomatous disease after gene therapy is calprotectin-dependent’’ in the 
Journal of Allergy and Clinical Immunology.2 They raise several interesting points, 
questioning our suggestion that formation of neutrophil extracellular traps (NETs) and NETs-
mediated killing of Aspergillus species might contribute to clearance in healthy individuals. 
We concluded this, because neutrophils from patients with chronic granulomatous disease 
(CGD) do not release NETs on contact with Aspergillus and as a consequence killing is 
impaired. In the following text, we discuss the comments of Roesler and Rösen-Wolff. 
Data on myeloperoxidase (MPO) deficiency (MIM #254600) were first published in 
1966 by the name of Alius-Grignaschi anomaly, which was defined as total hereditary 
peroxidase deficiency of neutrophils and monocytes in a healthy person in this publication. 
Epidemiological data on this rare disease are scarce and controversial (reference list 
available on request) incidence rates in the United States and Europe range from 1 case in 
2,000 (partial MPO deficiency) to 1 in 4,000 (complete MPO deficiency) population and from 
1 in 17,500 (partial MPO deficiency) to 1 in 57,135 (complete MPO deficiency) population in 
Japan. Some studies do not differentiate between partial and complete deficiency, whereas 
others report results only from screening of a small collective originating from a restricted 
geographical area; in addition, a uniform definition of complete MPO deficiency is lacking 
(eg, null mutation with the absence of protein expression vs hypomorphic mutation with 
impaired enzymatic function). Information on clinical consequences of complete MPO 
deficiency, especially with regard to infection, is rare, and a review is lacking to date 
(reference list available on request). Indeed, a more definitive epidemiological survey would 
be an important contribution to understanding MPO deficiency. 
Therefore, it is difficult to draw any conclusion as to susceptibility to infection of 
patients completely deficient in MPO. In addition, exposure to infectious agents might vary 
from one geographical region to another. As Roesler and Rösen-Wolff state correctly, 
Candida infections seem common in patients completely deficient in MPO3; however, 
disseminated infection with Aspergillus flavus and pulmonary infection with Aspergillus 
fumigatus3,4 as well as invasive bacterial infection with Staphylococcus aureus and 
Legionella have been described (references available on request). Thus, the increased 
susceptibility to infection might be linked to the absence of NETs formation in individuals 
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completely deficient in MPO and in patients with CGD,2,3 although definitive in vivo evidence 
is obviously lacking. 
Given the inability of completely MPO-deficient neutrophils to form NETs and some 
published evidence of susceptibility to infection, identification and a detailed clinical workup 
of further patients with complete MPO deficiency seems to be warranted in order to clarify its 
status as a primary immunodeficiency according to the WHO classification (Primary 
immunodeficiency diseases: an update from the International Union of Immunological 
Societies Primary Immunodeficiency Diseases Classification Committee Meeting in 
Budapest, 2005). Such a study would need to analyze genotype-phenotype correlation and 
susceptibility to infection and optimally comprise in vitro analyses of NETs formation on 
stimulation with identified disease-relevant pathogens. 
Susceptibility in murine models should be interpreted carefully, as clinical phenotypes 
in mice and men do not always correlate. Interestingly, earlier studies with human 
phagocytes showed that MPO-deficient as well as CGD neutrophils damage Aspergillus 
fumigatus hyphae equally inefficiently.5,6 Notably, hydrogen peroxide (a product of the 
nicotinamide adenine dinucleotide phosphate [NADPH] oxidase) or hypochlorous acid (a 
product of MPO) alone damaged Aspergillus hyphae only in concentrations ≥1 mM,5 and 
extracellular products of MPO did not rescue NETs formation in response to Candida 
albicans stimulation in patients completely deficient in MPO,3 suggesting that MPO acts cell-
intrinsically, independent of its enzymatic activity, most likely by driving chromatin 
decondensation during NETs formation.7 
To the best of our knowledge, NETs formation and NETs killing of Aspergillus species 
conidia or hyphae have not been analyzed yet in patients completely deficient in MPO. To 
address Roesler’s and Rösen-Wolff’s concerns, neutrophils of patients completely deficient 
in MPO should be analyzed parallely with those of patients with CGD and healthy controls 
and by adding products of MPO (eg, hypochlorous acid, histamine chloramines) and/or 
NADPH oxidase (eg, H2O2) to neutrophils. 
We therefore conclude that according to current knowledge, both NADPH oxidase 
and MPO are required for fungus-induced NETs formation. However, the apparent 
divergence of major pathogens related to CGD and complete MPO deficiency, concluded 
from scarce, thus potentially unreliable, epidemiological data in complete MPO deficiency, 
remains to be defined. 
 
Disclosure of potential conflict of interest: J. Reichenbach and M. Bianchi have received 
research support from the Chronic Granulomatous Disorders (CGD) Research Trust. The 
rest of the authors have declared that they have no conflict of interest. 
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Abstract 
 
Chronic granulomatous disease (CGD) is a primary immunodeficiency, caused by impaired 
function of phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, 
resulting in poor antimicrobial activity of neutrophils, including the inability to generate 
neutrophil extracellular traps (NETs). Recent phase I/II clinical X-CGD gene therapy (GT) 
trials with a gamma (γ)-retroviral long terminal repeat (LTR)-driven gp91phox vector proved 
efficacy of this treatment. Major drawbacks in these trials were transgene silencing and 
transactivation of oncogenes. Therefore new vectors with improved efficacy and safety are 
needed. We evaluated in vitro the efficacy of next generation γ-retroviral self inactivating 
(SIN) vectors, in which gp91phox expression is driven by cloned internal human myelospecific 
promoters. In an X-CGD (gp91phox-/-) murine model, NADPH oxidase reconstitution in 
transduced and differentiated human PLB-985 X-CGD and human lineage negative (Lin−) X-
CGD hematopoietic stem cells (HSC) highlighted two γ-retroviral SIN vectors, with MRP8 and 
miRNA-223 promoters, as candidates for future human X-CGD GT. In this model we showed 
that NET formation cannot be restored in PLB-985 X-CGD cells, even with functional NADPH 
oxidase. Only gene corrected Lin− X-CGD HSC could form NETs, suggesting that PLB-985 
X-CGD lack signaling leading to NET cell death, likely due to immortalization of this cell line. 
 
Introduction 
Chronic granulomatous disease (CGD) is a primary immunodeficiency in which one of 
the genes encoding phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase subunits is mutated, resulting in absent, or in rare cases limited, reactive oxygen 
species (ROS) production and poor microbial killing. Patients with CGD are susceptible to 
recurrent, severe, life-threatening bacterial and fungal infections 1. CGD is a suitable disease 
for hematopoietic stem cell (HSC)-targeted gene therapy (GT), as it arises from single gene 
defects in HSCs, and as the five defective genes have been cloned. 
As shown by recent human phase I/II clinical trials (in 2004 2 and 2007 3), GT for X-
linked gp91phox-deficient CGD (X-CGD) with a monocistronic gamma (γ)-retroviral long 
terminal repeat (LTR)-driven vector (SF71gp91phox), resulted in long-lasting engraftment of 
gene-corrected cells with therapeutic relevant levels of superoxide production, and lead to 
eradication of therapy refractory bacterial and fungal infections. However, unexpected later 
transgene silencing and oncogene transactivation leading to monosomy 7 and 
myelodysplastic syndrome (MDS) 2,4, mandate development of new vectors with sustained 
efficacy and safety. 
Next generation self inactivating γ-retroviral (SIN) vectors have been developed (in 
collaboration with Dr. Manuel Grez, Georg Speyer Haus, Frankfurt) that contain a deletion in 
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the U3 region of the 3’ viral LTR, resulting in the inactivation of the viral promoter/enhancer 
elements after reverse transcription 5,6. Transgene expression is driven by internal tissue-
specific human promoters (SP107 7, MRP8 8, miRNA-223 9), which lack enhancer activity 
and should not be prone to silencing, and are cloned 5’ to the gp91phox open reading frame 
(ORF). 
We studied all of these new vectors for ex vivo myelospecificity of gp91phox expression 
and reconstitution of NADPH oxidase function by in vitro transduction and differentiation of 
human PLB-985 X-CGD cells and human lineage negative (Lin−) HSC from an X-CGD donor. 
For the first time we included functional analysis of NADPH oxidase-dependent neutrophil 
extracellular trap (NET) formation and NET-Aspergillus killing 3,10 in the evaluation of vector 
efficacy. This is a better readout than standard nitrobluetetrazolium (NBT) and 
dihydrorhodamine-123 (DHR) assays, which only allow evaluation of ROS production. 
Here we show that, among the myelospecific vectors, MRP8 and miRNA-223 
promoters are the most efficient in driving gp91phox expression when used at multiplicity of 
infection (MOI) of 1, leading to sufficient ROS production for NET formation. 
 
Materials and methods 
Cell culture 
If not stated otherwise, HEK 293T-based Phoenix A (ΦNX A) cells (Nolan Lab) were grown in 
DMEM (PAA) + 10% fetal bovine serum (FBS) (PAA) + 2% Penicillin/Streptomycin (PS) 
(Gibco). Myeloid PLB-985 X-CGD 11,12 cells were kept undifferentiated in RPMI (PAA) + 10% 
FBS + 2% PS, or differentiated to granulocyte-like cells with 0.5% dimethylformamide (DMF) 
(Sigma) + 2.5% FBS (1 week) 13. Differentiation was confirmed by FACS by CD11b+ 
expression. Human Lin− HSC from control and X-CGD donors were isolated from apheresis-
mobilized peripheral HSC and bone marrow, respectively, by AutoMACS (Miltenyi) using 
Lineage Cell Depletion Kit (Miltenyi) and expanded undifferentiated in X-Vivo 10 (Lonza) + 2 
mM L-glutamine (Gibco) + 2% embryonic stem screened FBS (Hyclone) + 1% PS + 150 
ng/ml SCF + 150 ng/ml Flt3L + 50 ng/ml IL-3 + 50 ng/ml TPO, or differentiated to 
granulocyte-like cells over three weeks in RPMI + 2 mM L-glutamine + 10% FBS + 1% PS + 
50 ng/ml SCF (only first week) + 10 ng/ml Flt3L (only first two weeks) + 20 ng/ml G-CSF 
(during all three weeks). Differentiation was confirmed by FACS by CD15+ and CD11b+ 
expression. 
Cloning of γ-retroviral SIN vectors and production of viral particles 
The γ-retroviral pSER11M8delN91 SIN vector (kindly provided by Dr. Manuel Grez, Georg 
Speyer Haus, Frankfurt) was used as template for all constructs. This vector contains the 
internal human MRP8 promoter 5’ and the Woodchuck hepatitis virus post-transcriptional 
element (WPRE) 3’ of the gp91phox transgene, and a deleted 3’ U3 LTR region. The 
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constitutive active SFFV promoter and GFP sequences were amplified from the 
“pSER11.SF.GFP.W” vector (kindly provided by Dr. M. Grez). The myelospecific SP107 (SP 
for synthetic promoter) and miRNA-223 promoters were derived from “Lenti-sp107-GFP” 7 
(kindly provided by Senlin Li, University of Texas, Department of Medicine, USA) and “223-
1gpsW” vectors (kindly provided by Dr. M. Grez). Recombinant plasmids were introduced by 
heat shock into E. coli Top-10 competent cells (Invitrogen). DNA extraction and purification 
were performed according to standard procedures using commercial kits (Quiagen, 
Macherey-Nagel). All cloned vectors were checked by restriction digestion and agarose gel 
electrophoresis. Sequences were confirmed by DNA sequencing (ABI PRISM 3130xl Genetic 
Analyzer, Applied Biosystems). 
Amphotropic infectious particles were generated by transient transfection of ΦNX A 
cells. In 15 cm plates, 70-80% confluent ΦNX A cell layers (in 15 ml media) were co-
transfected with 20 µg pUMVC (γ-retroviral Gag-Pol), 10 µg VSV-G (Env) and 80 µg 
transgene vectors by 4 µl TransIT-293 reagent (Mirus) per µg of total DNA. Viral particle 
containing supernatants were collected 24 and 48 h after transfection, sterile filtered through 
0.45 µm PVDF membranes (Millipore) and concentrated from 15 ml to 500 µl using 100 kDa 
cutoff centrifugal filter units (Amicon-Ultra 15, Millipore). Concentrated viral supernatant was 
aliquoted (10 µl) and kept at -80°C until use. 
Transduction of PLB-985 X-CGD and human Lin− HSC X-CGD cells 
For titration, PLB-985 X-CGD cells were transduced by spinoculation (90 min, 2500 RPM, 
32°C) with serial dilutions of viral supernatants in presence of 8µg/ml protamine sulfate 
(Sigma). Transduction rate was measured 3 days later by flow cytometry (FACS Calibur, BD 
Biosciences). As transduction efficiencies above 20 % result in a significant portion of cells 
with more than one integration 14 we calculated the titers from those dilutions resulting in a 
maximum of 20% transgene positive cells, using the formula: Titer (Transducing Units 
(TU)/ml) = seeded cell number x dilution factor of viral supernatant x (transgene positive cells 
(%)/100%). For transgene expression analysis, transduced PLB-985 X-CGD cells were either 
kept undifferentiated or differentiated to granulocyte-like cells in 0.5% DMF. For functional 
analysis, MOI 1 transduced cells (< 20% transduction rate) were first stained with 10 µg/ml 
gp91phox-FITC and sorted with anti-FITC beads by AutoMACS (Miltenyi) to obtain gp91phox+ 
cells, then either expanded undifferentiated or differentiated to granulocyte-like cells 15. 
 Human Lin− HSC were transduced on 10 μg/cm2 Retronectin (TaKaRa) precoated 
plates. Coating was performed following product instructions. Afterwards, γ-retroviral 
supernatants were first loaded onto Retronectin-coated plates by centrifugation (3000 RPM 
for 30 min at 4°C), then Lin− HSC were seeded, centrifuged 5 min at 300 g and expanded 
undifferentiated for up to 7 days or differentiated to granulocyte-like cells over 3 weeks for 
further functional analysis. 
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NADPH oxidase function analysis and NET formation 
NADPH oxidase activity was determined by DHR oxidation 16 and by nitrobluetetrazolium 
(NBT) reduction 17 as described. The amount of O2- produced by phorbol 12-myristate 13-
acetate (PMA) stimulated cells was quantified by Fe3+ cytochrome c reduction as described 
2,18. NET formation was analyzed by 6 h incubation of 5x104 cells/well (standard cell culture 
96 well plate, TPP) in RPMI (without phenol red) + 5 mM Hepes + 40 nM PMA. NETs were 
fixed in 4% paraformaldehyde, stained with 5 µM Sytox green (Invitrogen) and visualized 
using an inverted light microscope (Leica DM IL HC Fluo) with a 100 W mercury lamp (106z, 
Leica) and a GFP filter (GFP Filter Cube, Leica). Images were taken using a CCD camera 
(DFC 480 R2, Leica) coupled to the microscope. 
 
Results 
Next generation γ-retroviral SIN vectors 
pSF71gp91, the LTR driven vector used in previous GT clinical trials for treatment of X-CGD 
2,3, will be replaced by new generation γ-retroviral SIN vectors (Figure 1) in future GT clinical 
trials. New vectors have a codon optimized gp91phox sequence, deleted 3’ LTR enhancer, 
and TATA box and internal myelospecific promoters to drive transgene expression. All 
vectors were cloned using pSER11M8delN91 as template. Two myelospecific promoters 
(SP107 and miRNA-223) and for comparison a strong constitutively active viral promoter 
(SFFV) were cloned. gp91phox was replaced by GFP as control vector and for setup 
experiments. Viral titers were initially low in PLB-985 X-CGD cells, therefore intense 
optimization work using GFP vector was performed resulting in a protocol which in summary 
required: adjusted plasmid amounts, lipid-mediated co-transfection and viral particles 
concentration. A 1000-fold increase of titers, from 104 TU/ml to up to107 TU/ml, was achieved 
following this protocol, with differences between vectors (Table 1). 
 
 
Table 1. Viral titers 
Vector Titers (TU/ml) 
pSF71gp91 3.40x106 
pSER11SFFVGFP 1.20x107 
pSER11SFFVgp91 1.15x107 
pSER11SP107delN91 4.08x106 
pSER11M8delN91 1.59x107 
pSER11miR223delN91 1.02x107 
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Figure 1. Next generation γ-retroviral SIN vectors. Previously used LTR-driven vector (pSF71gp91) and 
new generation of cloned γ-retroviral SIN vectors are shown. SIN vectors contain the Woodchuck 
hepatitis virus post-transcriptional element (WPRE) 3’ of the transgene and a deleted enhancer and TATA 
box in the 3’ LTR U3 region. Transgene expression is driven by internal promoters. SFFV = Spleen Focus 
Forming Virus promoter; SP107 = synthetic promoter composed by nine PU.1 transcription factors 
binding sites; MRP8 = S100A8 (Calgranulin A) promoter; miR223 = micro RNA 223 promoter. 
 
 
Myelospecificity of next generation γ-retroviral SIN vectors 
To screen for myelospecificity, premyeloid PLB-985 X-CGD cells were used. Cells were 
transduced with all gp91phox encoding γ-retroviral vector constructs, then differentiated to 
granulocyte-like cells. CD11b staining showed good differentiation after 1 week in 0.5% 
DMF, more than 95% of the cells were CD11b+ as analyzed by FACS. There was no 
difference in gp91phox expression between undifferentiated and differentiated PLB-985 X-
CGD cells, when transgene expression was driven by the strong and non-myelospecific 
SFFV promoter (SF71gp91 and SFFVgp91, Figure 2). Unexpectedly, gp91phox expression 
was 50% lower in differentiated cells with SP107gp91 vector, with very low “mean 
fluorescence intensity” (MFI) of the gp91phox+ cell population, indicating that only low 
transgene expression could be obtained by using the SP107 promoter. MRP8gp91 and 
miR223gp91 vectors showed more promising results with an increase of around 52% and 
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14% of gp91phox expressing neutrophils-like cells and 6% and 18% increase of transgene 
expression (MOI), respectively, after cell differentiation (Table 2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Myelospecificity of γ-retroviral SIN vectors. Myeloid PLB-985 X-CGD cells were transduced with 
all gp91phox γ-retroviral vectors and then differentiated to granulocyte-like cells in 0.5% DMF. gp91phox 
expression was compared in undifferentiated (CD11b−) and differentiated (CD11b+) cells. SF71gp91 and 
SFFVgp91 are used as constitutively active promoter/vector controls. Among other promoters, MRP8 and 
miR223 showed the highest myelospecific gp91phox expression after differentiation, with an increase of 
around 52% and 14% of transgene expressing cells, and 6% and 18% increase of transgene expression 
(MOI), respectively. SP107 gp91phox driven expression was the lowest. 
 
 
As all promoters were already active in undifferentiated PLB-985 X-CDG cells, it is difficult to 
evaluate precisely any change in transgene expression in this cell line. As PLB-985 X-CDG 
is a premyeloid cell line, such cells are not enough undifferentiated, and the measured 
activity of the three myelospecific promoters in undifferentiated, yet premyeloid cells, is 
therefore not surprising. 
 
 
Table 2. Myelospecificity of γ-retroviral vectors in PLB-985 X-CGD cells (¢) 
Vector % gp91phox+ in undif. ¢ % gp91phox+ in dif. ¢ ∆% ¢ upon dif. ∆% MFI upon dif. 
pSF71gp91 16.12 15.79 -2.05 -0.97 
pSER11SFFVGFP 34.69 36.44 +5.04 -6.93 
pSER11SP107delN91 18.02 8.81 -51.11 +6.58 
pSER11M8delN91 14.39 21.86 +51.91 +5.97 
pSER11miR223delN91 22.41 25.45 +13.57 +18.30 
Abbreviations: undif = undifferentiated; dif = differentiated; ¢ = cells 
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Reconstitution of NADPH oxidase function in PLB-985 X-CGD cells 
To better study functionality of gp91phox γ-retroviral SIN vectors, MOI 1 transduced PLB-985 
X-CGD cells were sorted after gp91phox staining by AutoMACS, then expanded. One week 
culture in 0.5% DMF resulted in more than 90% differentiated cells, as shown by CD11b 
staining. After sorting, more than 80% of cells were CD11b/gp91phox+/+ (Figure 3A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Reconstitution of NADPH oxidase function in PLB-985 X-CGD cells. MOI 1 transduced PLB-985 
X-CGD gp91phox expressing cells were sorted by AutoMACS and differentiated in 0.5% DMF (A). NADPH 
oxidase function was assessed by DHR (B) and NBT (C) assays, showing that MRP8gp91 and 
miR223gp91 were the most efficient vectors to reconstitute NADPH oxidase activity (the strong SFFVgp91 
vector was used as control). SP107gp91 vector showed poor functionality: at MOI 1 not all gp91phox 
expressing cells were able to reconstitute function (D). O2- quantification by cytochrome c Fe3+ reduction 
(E-F) confirmed DHR and NBT results: O2- production by MRP8gp91 and miR223gp91 were comparable to 
SFFVgp91 transduced cells, whereas in SP107gp91 transduced cells O2- production was insufficient. 
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Only cells transduced with the SP107gp91 vector resulted in lower CD11b/gp91phox+/+ 
numbers (52%), as the sorted gp91phox+ population was less pure due to the very low 
gp91phox expression driven by the SP107 promoter (Figure 2). 
 For testing functionality, ROS-production of transduced cells was first analyzed by 
DHR test (Figure 3B). Reconstitution of NADPH function was very efficient when SFFVgp91, 
MRP8gp91 and miR223gp91 vectors were used, with more than 80% DHR positive cells. 
The SP107gp91 vector could only partially restore ROS production, with only 27% DHR 
positive cells. These results were then confirmed by NBT assay, with a blue precipitate 
(formazan) being extensively formed with all vectors but SP107gp91 (Figure 3C). 
Comparison of CD11b/gp91phox+/+ expression, DHR and NBT data showed good correlation 
between gp91phox expression and NADPH oxidase function when cells were transduced with 
SFFVgp91, MRP8gp91 and miR223gp91 vectors (Figure 3D), i.e. expression of a single 
transgene copy/cell driven by these promoters is enough to establish sufficient functionality. 
This was not the case for the SP107gp91 vector. 
ROS production was then quantified by cytochrome c Fe3+ reduction (Figure 3E), 
showing that O2- production was, as expected, more than 3.5-fold lower in SP107gp91 
transduced cells compared to cells transduced with all other vectors (Figure 3F, values 
normalized to CD11b/gp91phox+/+ expression). MRP8gp91 and miR223gp91 vectors behaved 
again very similar to each other, with only slightly lower O2- production compared to the 
strong SFFVgp91 vector. Normal healthy neutrophils were used as reference. 
NET formation in transduced PLB-985 X-CGD cells 
Activated neutrophils kill microbes via phagocytosis and by extracellular mechanisms 
including Neutrophil Extracellular Traps (NETs). NETs are composed of chromatin (DNA and 
histones) decorated with granular proteins 19. These structures bind bacteria 19 and fungi 20 
and provide a high local concentration of antimicrobial molecules. Generation of NETs 
requires the production of ROS by the NADPH oxidase, therefore is deficient in CGD 21. 
To further test functional efficacy of next generation vectors, NET formation was 
therefore studied in all transduced PLB-985 X-CGD cells. After 6h stimulation with PMA, NET 
formation was visualized in all transduced and sorted cells by DNA stain and fluorescence 
microscopy analysis. No NETs were formed by transduced, NADPH oxidase expressing and 
ROS producing PLB-985 X-CGD cells, likely because of the immortalization characteristics of 
this cell line. Figure 4 shows normal healthy neutrophils as control, with compact and 
multilobated nuclei while unstimulated, and decondensed NET-DNA upon PMA stimulation. 
In contrast, PLB-985 X-CGD cells transduced with the SFFVgp91 vector (as representative 
result only the strongest vector is shown) did not show any significant difference between 
unstimulated and stimulated cells. Only very few (< 5%) PMA activated cells showed a NET-
like structure, and not more than 80% as it was expected from DHR and NBT data (Figure 3).
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Figure 4. NET induction in transduced PLB-985 
X-CGD cells. MOI 1 transduced PLB-985 X-
CGD gp91phox expressing cells were sorted by 
AutoMACS and differentiated in 0.5% DMF. 
NETs were induced by 6 h incubation with 40 
nM PMA, NET-DNA was stained with 5 µM 
Sytox green after fixation in 4% para-
formaldehyde and visualized by fluorescence 
microscopy. Healthy neutrophils were used as 
control, showing full NET formation after PMA 
stimulation (left lower panel, arrow shows a 
representative NET-cell). In contrast, PLB-985 
X-CGD cells transduced with the strong 
SFFVgp91 vector were not able to make NETs 
efficiently (< 5% right lower panel). 
 
 
 
 
ROS production and reconstitution of NET formation in Lin− X-CGD HSC 
To overcome above mentioned problem with immortalized PLB-985 X-CGD cells, the same 
functional NET assay was performed using human Lin− HSC isolated from apheresis-
mobilized peripheral HSC of a healthy donor and Lin− HSC isolated from bone marrow of an 
X-CGD patient. Lin− HSC were pre-stimulated to induce cell division (as γ-retroviral vectors 
do not integrate in resting cells), transduced with MOI 1 on Retronectin and further cultured 
(Figure 5). 
 
Figure 5. Culture and 
differentiation of human Lin− 
HSC. Human Lin− HSC were 
isolated from apheresis-
mobilized peripheral HSC of 
an healthy donor and bone 
marrow of an X-CGD patient 
by AutoMACS. After 3 days 
pre-stimulation, cells were 
transduced (at MOI 1) and 
expanded undifferentiated for 
1 week or differentiated to 
granulocyte-like cells over 3 
weeks. Differentiation was 
determined by CD15/CD11b+/+ 
expression and by microsco-
pical analysis of multilobated 
nuclei (arrow in lower right 
panel). 
 
Due to lower cell numbers available and limited in vitro expansion possibilities (compared to 
PLB-985 X-CGD cells, Lin− HSC are slow dividing cells and cannot be expanded indefinitely 
as they easily start to self-differentiate in different cellular subtypes), transduced X-CGD Lin− 
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HSC were not sorted for gp91phox expression. Differentiation was assessed by FACS analysis 
of CD15+ and CD11b+ expression, and by microscopical analysis for presence of 
multilobated nuclei. After 3 weeks differentiation, neutrophil-like cell (CD15/CD11b+/+) 
formation rate was estimated to be around 45% by FACS (not shown), confirmed by 
microscopical evaluation of nuclear shape (Figure 5). As expected, FACS analysis of 
gp91phox expression in transduced cells showed that transduction of X-CGD Lin− HSC cells 
with γ-retroviral vectors was not as efficient as in PLB-985 X-CGD cells, as cell division of 
Lin− HSC is not as fast as cell division in cell lines. Transduction rate was around 11% with 
SFFVgp91 vector, 4-6% with MRP8gp91 and miR223gp91 vectors and only 1% with 
SP107gp91 vector (not shown), confirming the low transduction efficiency of the SP107 
promoter. NADPH oxidase dependent ROS production was restored after transduction and 
differentiation of X-CGD Lin− HSC, as shown by DHR and NBT tests (Figure 6A-B), in good 
correlation with CD15/CD11b+/+ and gp91phox+ expression. In contrast to transduced PLB-985 
X-CGD cells, PMA stimulation and DNA staining evidenced NET formation in control, 
SFFVgp91, MRP8gp91 and miR223gp91 transduced and differentiated X-CGD Lin− HSC 
cells, as shown by fluorescence microscopy (Figure 6C). Extent of NET formation was 
comparable to NBT results (Figure 6B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Reconstitution of NADPH oxidase dependent ROS production and NET formation in human Lin− 
HSC. Untransduced normal healthy human Lin− HSC, and untransduced and MOI 1 transduced human X-
CGD Lin− HSC were differentiated to granulocyte-like cells over 3 weeks. NADPH oxidase dependent ROS 
production was assessed by DHR (A) and NBT (B) assays, showing that MRP8gp91 and miR223gp91 were 
most efficient (the strong SFFVgp91 vector was used as reference, together with untransduced healthy 
Lin− HSC). SP107gp91 vector was unable to restore sufficient ROS production. NETs were induced by 6 h 
incubation with 40 nM PMA, NET-DNA was stained with 5 µM Sytox green after fixation in 4% 
paraformaldehyde and visualized by fluorescence microscopy (C). In contrast to transduced PLB-985 X-
CGD gp91phox+ cells, NETs were formed by transduced and differentiated Lin− HSC, in good correlation 
with DHR and NBT results. 
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Discussion 
CGD is an attractive target for GT because it is caused by a single gene defect, it can be 
reproduced in vitro and because the genetic correction does not need to be complete to 
provide full protection against infections 22. Data from variant forms of CGD and from healthy 
female carriers of X-CGD with 10% normal neutrophils suggest that correction of the 
phenotype in a fraction of CGD cells could be sufficient to alleviate the symptoms of the 
disease 23. 
γ-retroviral vectors have been largely studied over the years and phase I/II clinical 
trials of gene therapy against X-CGD proved the feasibility of this approach 2,3. Side effects 
like silencing and transactivation 2,4 imposed the improvement of vector efficacy and safety, 
leading to the development of SIN vectors 5,6. In contrast to lentiviral vectors, γ-retroviral 
vectors can only infect dividing cells. Titers of produced viral particles are lower using γ-
retroviral vectors compared to lentiviral vectors, which is a problem transducing slowly 
dividing HSC. The first important step in our vector screen was therefore the improvement of 
viral titers with a 3-log factor, from 104 TU/ml to up to107 TU/ml, by optimization of plasmid 
concentrations utilized for virus production, lipid transfection and concentration of viral 
particles. Clinically, high viral titers are important because they allow shorter ex vivo culture 
as they need less HSC transduction rounds, which may help preserve the engraftment 
capacity of the HSC for long term correction 24. 
Among the three myelospecific promoter containing vectors tested with regard to 
transgene expression and NADPH oxidase function, vectors containing MRP8 and miRNA-
223 promoters are the most promising for future clinical use. Both vectors restored strong 
gp91phox expression and O2- production in transduced and differentiated PLB-985 X-CGD 
cells, comparable to a strong SFFV-driven SIN vector. The fact that NADPH oxidase function 
was fully restored at MOI of 1 is of importance with regards to vector safety, as multiple 
integrations have to be avoided to lower the risk of transactivational adverse events. 
SP107gp91 vector showed the lowest NADPH oxidase reconstitution potential in the studied 
models. gp91phox expression driven by the SP107 promoter was too low for sufficient ROS 
production when used at MOI of 1. O2- production was 3.5-fold lower compared to the other 
myelospecific vectors, barely enough to give a positive DHR or NBT signal in the few 
corrected cells. 
Myelospecificity was difficult to assess when comparing undifferentiated to 
differentiated transduced PLB-985 X-CGD cells as PLB-985 is a pre-myeloid cell line 11, 
already partially differentiated into the monocytic/neutrophilic direction. It is therefore not 
surprising that all myelospecific promoters used in our screen were already active in 
undifferentiated transduced PLB-985 X-CGD cells. After differentiation, only MRP8 and 
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miRNA-223 promoters showed slight improvements in gp91phox expression, but the PLB-985 
X-CGD model proved to be non-optimal to study promoter myelospecificity.  
As we have previously shown the importance for NADPH oxidase-dependent NET 
formation in anti-Aspergillus defense 3,10 we included NET formation assays in our vector 
screen, allowing to study for the first time NADPH oxidase functional reconstitution. Unluckily 
transduced and differentiated PLB-985 X-CGD cells (and normal PLB-985 cells with 
functional NADPH oxidase) were not able to form NETs upon stimulation. This is presumably 
due to the immortalized characteristics of the cell line, precluding a cell death program as 
NETosis. We therefore performed the vector screen using human Lin− HSC isolated from an 
X-CGD patient. DHR and NBT results confirmed efficient NADPH oxidase reconstitution in 
terms of ROS production with MRP8gp91 and miR223gp91 vectors. SP107gp91 was 
inefficient in correcting the defect. NET formation was efficiently restored after transduction. 
As mentioned above, the limiting factor using γ-retroviral vectors is their inability to infect 
non-dividing cells, as shown by the low percentage (4-10%) of transduced cells when using a 
single transduction round and MOI 1 protocol. For clinical purpose, at least a second 
transduction round would therefore be necessary in order to have > 10% NADPH oxidase 
functional neutrophils. 
Myelospecificity was difficult to assess in transduced Lin− HSC, as undifferentiated 
Lin− HSC cannot be expanded efficiently and as stem cells properties are quickly lost during 
in vitro culture. Transgene expression in undifferentiated Lin− HSC, even with myelospecific 
promoters, may be caused by the presence of unintegrated circular DNA 25 which could not 
get lost by dilution during cell divisions. Therefore there is a risk to compare multiple copies 
of unintegrated circular DNA in Lin− HSC or progenitor cells with a single copy of integrated 
transgene in differentiated granulocyte-like cells (where unintegrated DNA get diluted by 
sustained cell division during the three weeks differentiation process). 
In conclusion, our screens show that the SP107 promoter cannot be considered a 
candidate for human X-CGD GT, due to insufficient transgene expression. The use of this 
synthetic promoter, with nine repetitive PU.1 sites 7, would anyway need to be analyzed very 
carefully, as repetitive sequences within retroviral genomes are unstable and frequently 
deleted upon reverse transcription 26,27. In contrast, vectors harboring the MRP8 and miRNA-
223 promoters are eligible for further safety-centered studies, to be finally considered for 
future human X-CGD GT trials.  
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CGD is a rare primary immunodeficiency, with an estimated frequency of 1 in 200’000 live 
births. Defective phagocyte NADPH oxidase function accounts for impaired ROS production 
and poor microbial killing, leading to recurrent life-threatening bacterial and fungal infections 
in patients with CGD. Overall mortality is a serious issue (among all patients who do not get 
BMT), with about 13-20% of the patients not surviving the disease despite adequate 
antibiotic and antifungal prophylaxis 1-3. Aspergillus spp infections, which cause pneumonia 
and disseminated disease, are frequently refractory to antifungal therapy, treatment with 
interferon-γ, or granulocyte transfusions 4, and are the leading cause of death in CGD 
patients 3-6. 
 
Objectives 1 and 2 
Up to now, it was unclear how normal human neutrophils control the significantly larger 
Aspergillus hyphae which are too big for phagocytosis 7-13. We elucidated the neutrophil 
immune response and mechanism against Aspergillus infection (chapters 1 and 2): 
Objective 1: We demonstrated that the recently discovered NADPH oxidase 
dependent extracellular microbicidal pathway through NETs is acting efficiently against A. 
nidulans conidia and hyphae in vitro, and that restoration of NET formation by 
complementation of NADPH oxidase function by GT in a patient with X-linked CGD aided 
clearing severe invasive A. nidulans infection in vivo (Bianchi et al, Blood 2009 14). 
Objective 2: The antifungal agent responsible for control of A. nidulans within NETs 
was identified to be the Zn2+-chelator calprotectin. The calprotectin heteroduplex formed by 
subunits S100A8 and S100A9 belongs to the calcium-binding protein family of S100 proteins, 
and exerts strong microbistatic activity against a variety of microorganims in vitro. We 
established that calprotectin released in NETs displays concentration-dependent reversible 
and irreversible growth inhibitory activity against virulent A. nidulans: it was fungistatic at low 
concentrations (< 16ng/ml) and fungicidal at high concentrations (> 16ng/ml), which closer 
mimic the physiological situation in human abscesses (1-20 mg/ml found in such abscesses 
15). NETs therefore seem to be involved in disarming A. nidulans and may prevent further 
spreading by providing high local concentrations of calprotectin (Bianchi et al, JACI 2011 16). 
 
In conclusion of objectives 1 and 2 
As the presence of a functional NADPH oxidase in human neutrophils was shown to be an 
absolute requirement for A. nidulans growth inhibition and fungal starvation by NET-
associated calprotectin, we propose that NET formation is an NADPH oxidase-dependent 
mechanism by which neutrophils secrete calprotectin into the extracellular compartment 
upon infection with Aspergillus hyphae. NET-associated calprotectin is concentrated with 
trapped Aspergillus for antifungal function. Unbound calprotectin may additionally serve for 
distinct functions, such as chemotaxis or inflammation. 
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Outlook concerning objectives 1 and 2 
Since, for ethical reasons, the role of NETs in antimicrobial defense is difficult to monitor in 
humans in vivo, we are currently developing an in vivo infection model using CGD mice, 
involving subcutaneous injection of bioluminescent Aspergillus hyphae. NET formation and 
clinical as well as histological granuloma resolution will be monitored before and after GT in 
these mice. The aim of this assay is to correlate NET formation to NADPH oxidase gene 
expression and reconstitution of NADPH oxidase function to enable choice of the adequate 
next generation GT vector for future human clinical CGD GT trials. 
 
GT approaches to cure CGD have been developed in the past years as an alternative to 
CGD patients needing HSCT, but lacking an HLA-matched HSC donor 5,14,16-20. Despite 
clinical success with resolution of life-threatening therapy refractory infections in 4 patients (2 
adults treated in Frankfurt University, and 2 children treated in our Division of 
Immunology/Hematology/BMT in Zurich) with X-linked CGD, two major drawbacks occurred 
during the clinical GT trial: silencing of the transgene with significant decline of NADPH 
oxidase function, and transactivation of oncogenes leading to clonal expansion and MDS in 
3/4 patients 21. 
 
Objective 3 
Transactivation and silencing events impose the development of alternative GT vectors with 
improved safety and efficiency properties. Therefore, in collaboration with Dr. Manuel Grez 
(Georg Speyer Haus, Frankfurt, Germany), we developed next generation γ-retroviral SIN 
vectors as candidates for future X-CGD GT trials (chapter 3). These vectors contain a 
deletion in the U3 region of the 3’ viral LTR, resulting in the inactivation of the viral 
promoter/enhancer elements after reverse transcription 22,23. Transgene expression is driven 
by internal tissue-specific human promoters, which lack enhancer activity and should not be 
prone to silencing. Among the myelospecific vectors tested, we identified the MRP8 24 and 
miRNA-223 25 promoters to be the most efficient in vitro to drive gp91phox expression when 
used at MOI 1 in human HSC. The X-CGD PLB cell line model proved to be inefficient for 
testing these vectors, as PLB cells did not form NETs (see objective 1). Only transduced and 
differentiated human Lin− HSC could form NETs in vitro upon stimulation. 
 
In conclusion of objective 3 
Our study has lead to identification of pSER11M8delN91 and pSER11miR223delN91 as 
promising candidates for the next clinical X-CGD GT phase I/II trial, conferring sufficient 
transgene expression and functional correction of the NADPH oxidase defect with regards to 
anti-infectious NET-formation. For authorization purposes (Swissmedic), genotoxicity and 
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silencing studies are currently under way, so that the next vector for clinical use will hopefully 
be available by 2012. 
 
Outlook concerning objective 3 
The goal of GT in CGD is to achieve a stable population of gene corrected myeloid 
precursors, which give rise to a biologically significant number of functional peripheral 
phagocytes. In order to better evaluate the myelospecificity of above tested vectors and their 
efficacy in reconstituting antimicrobial defense against pathogens, in vivo studies need to be 
performed in an X-CGD mouse GT model, which will provide more precise information about 
transgene expression in different blood cell subsets. 
 
Prospects and Perspectives 
In addition to the safety issues which are currently addressed in vector development for CGD 
GT, successful GT for CGD is also limited by the transduction efficiency of myeloid 
precursors ex vivo and by the ability of corrected cells to replace uncorrected cells in vivo. 
Concerning efficiency, the use of an in vivo selectable marker may allow sustained 
persistence of gene-modified cells at therapeutic relevant levels, although the long-term 
implications of cytotoxic drug treatment remains a safety concern 26. To prevent loss of 
transgene expression, the ubiquitously-acting chromatin opening element (UCOE) has been 
shown to resist silencing and produce persistent transgene expression in a mouse study 27. 
In addition, chromatin insulators such as the chicken β-globin hypersensitive site 4 have 
been used successfully to shield the surrounding chromatin from the vector and vice versa 
the vector from influences by the surrounding chromatin, resulting in less position-dependent 
silencing and in less position-effect variegation 28. In addition, lentiviral vectors are now being 
developed and tested for a variety of primary immunodeficiencies, encouraged by the recent 
first clinical success achieved in X-linked adrenoleukodystrophy (ALD) where a SIN-lentiviral 
vector in combination with conventional myeloablative conditioning were used 29. Cartier et 
al. reported polyclonal reconstitution up to 24 to 30 months from GT, with 9 to 15% 
granulocytes, monocytes, T and B lymphocytes expressing the ALD protein. The advantage 
of lentiviral vectors over γ-retroviral vectors is their higher potential to transduce non-dividing 
stem/progenitor cells avoiding the need for strongly stimulating cell proliferation by cytokines 
during ex vivo culture. This allows for shorter transduction protocols reducing the risk of graft 
failure and assembly of chromosomal aberrations during prolonged ex vivo culture. 
According to mouse and large animal studies the integration pattern of lentiviral vectors is 
favorable (compared to γ-retroviral vectors) with a potentially lower risk of insertional 
mutagenesis 30-32. 
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Concerning safety, alternatively to the above mentioned approaches with 
myelospecific SIN vectors, gene correction may be achieved by taking advantage of cellular 
homologous recombination (HR), one of the major mechanisms for repairing DNA damage, 
which occur normally during chromosome replication. Zinc finger nucleases are synthetic 
fusion proteins that combine multiple zinc finger motifs, each capable of binding to specific 
DNA sequences, with a nuclease that can introduce a DNA break 33. They might provide 
integration of the transgene into a so called “safe genomic harbor” (such as the AAVS1 locus 
on human chromosome 19 34) 35,36. Even if very promising, this strategy is still far from clinical 
application 37. The efficacy and potential genotoxicity of such gene correction method have to 
be well studied but, if safe and effective, this approach could in the future replace gene 
addition approaches for GT of CGD. 
In conclusion, despite considerable progress in the past years, clinical GT for genetic 
diseases such as CGD remains a field in its infancy, yet/and is opening up fascinating 
research perspectives. 
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Abbreviations 
AAV adeno-associated virus 
ADA-SCID adenosine deiminase-SCID 
ALD adrenoleukodystrophy 
BM bone marrow 
BMT bone marrow transplantation 
CFU colony forming unit 
CGD chronic granulomatous disease 
DAPI 4’,6-diamidino-2-phenylindole 
DHR dihydrorhodamine 
DMF dimethylformamide 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
ds double stranded 
ELISA enzyme-linked immunosorbent assay 
Env envelope gene 
Evi1 ecotropic viral integration 1 site 
FACS fluorescence-activated cell sorter 
FAD flavin adenin dinucleotide 
FBS fetal bovine serum 
FDG fluorodeoxyglucose 
FITC fluorescin isothiocyanate 
Flt3L Fms-related tyrosine kinase 3 ligand 
Gag group-specific antigen gene 
GALV gibbon ape leukemia virus 
G-CSF granulocyte-colony stimulating factor 
GDP guanosine diphosphate 
GFP green fluorescent protein 
GT gene therapy 
GTP guanosine triphosphate 
GVHD graft-versus-host disease 
H2O2 hydrogen peroxide 
HEK human embryonic kidney 
HGMD Human Gene Mutation Database 
HIV human immunodeficiency virus 
HLA human leukocyte antigen 
HOBr hypobromous acid 
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HOCl hypochlorous acid 
HR homologous recombination 
HSC hematopoietic stem cell 
IDO indoleamine 2,3-dioxygenase 
IFN-γ interferon-gamma 
IL interleukin 
Lin− lineage negative cells 
LMO2 LIM domain only 2 
LRR leucine-rich repeat 
LTR long terminal repeat 
MDS1 myelodysplastic syndrome 1 
MFI mean fluorescence intensity 
miRNA-223 microRNA-223 
MLV murine leukemia virus 
MMP matrix metalloproteinase 
MNase micrococcal nuclease 
MOI multiplicity of infection 
MPO myeloperoxidase 
MRP8 migration inhibitory factor-related protein 8 
MyD88 myeloid differentiation primary-response protein 88 
NADPH reduced nicotinamide adenine dinucleotide phosphate 
NBT nitroblue tetrazolium 
NE neutrophil elastase 
NET neutrophil extracellular trap 
NOX NADPH oxidase 
O2− superoxide 
OH− hydroxyl radicals 
ORF open reading frame 
PAD4 peptidylarginine deiminase 
pDC plasmacytoid dendritic cell 
PET-CT positron emission tomography-computed tomography 
PHOX phagocyte oxidase 
PI3K phosphatidylinositol 3-kinase 
PMA phorbol 12-myristate 13-acetate 
Pol polymerase gene 
PPT polypurine-tract 
PRDM PR domain 
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Pro protease gene 
Psi (ψ) packaging signal 
PU.1 purine rich box-1 
RNA ribonucleic acid 
ROS reactive oxygen species 
SCF stem cell factor 
SCID severe combined immunodeficiency 
SD standard deviation 
SEM scanning electron microscopy 
SFFV spleen focus-forming virus 
SH Src homology 
SIN self-inactivating 
SLE systemic lupus erythematosis 
SOD superoxide dismutase 
SP107 synthetic promoter 107 
ss single stranded 
TPO thrombopoietin 
TU transducing unit 
UCOE ubiquitously-acting chromatin opening element 
VSV vesicular stomatitis virus 
WPRE woodchuck hepatitis virus post transcriptional regulatory element 
X-CGD X-linked CGD 
XTT 2,3-bis(2-Methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide 
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